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Abstract 
Individuals with Alzheimer Disease (AD) exhibit deficits across multiple cognitive 
domains years before clinical diagnosis, when they are in the preclinical stages of the 
disease. Four studies were conducted to (a) examine the preclinical neuropsychological 
characteristics of English- and French-speaking Alzheimer Disease (AD) participants 
from the Canadian Study of Health and Aging (CSHA) and (b) determine the utility of 
select CSHA neuropsychological and demographic measures in predicting AD over a 
five-year period. Both English- and French-speaking AD participants demonstrated 
cognitive changes on episodic memory, verbal fluency, and speeded visuomotor 
processing tasks five years prior to diagnosis, however declines in performance between 
initial- and re-assessment were not uniform across these domains for either language 
group. Advanced age and declines in delayed episodic memory were the most 
significant indicators of progression to AD over a five-year period for both language 
groups. A validation study was conducted to investigate how well the predictors of AD 
prognosticate diagnostic outcome for an independent group of at-risk English-speaking 
participants. The best predictors of AD for the English-speaking group (age, episodic 
memory, and speeded visuomotor processing) accurately classified close to 70% of 
individuals from the at-risk sample. The present findings will contribute to diagnostic 
decisions regarding AD in older English- and French-speaking Canadian adults.   
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Introduction 
As the average life expectancy continues to rise, Alzheimer disease (AD), the 
most common cause of dementia, will become an increasingly prevalent condition and 
public health care concern in Canada (Diamond, 2005). AD is a progressive 
neurodegenerative disorder that is characterized by relentless declines in cognitive 
abilities that have a devastating impact on an individual’s behavioural and social 
functioning; AD eventually causes death. At the present time, approximately 280 000 
Canadians over the age of 65 are living with AD and this level is projected to reach over 
half a million by the year 2031 (Diamond, 2005). The prevalence of AD is highest in 
seniors 85 years of age and older (approximately 26%), which is also the fastest growing 
segment of the population (Canadian Study of Health and Aging Working Group, 1994). 
In addition, approximately $5.5 billion dollars are being spent on persons with AD and 
related dementias in Canada each year1.  
The advent of pharmacological, psychoeducational, and behavioural treatments 
for individuals with AD has led to increasing interest in reliably diagnosing this condition 
in the earliest stages. Research over the last two decades has revealed that subtle 
neuropsychological deficits precede diagnostically significant cognitive, behavioural, and 
social changes by years (Bondi & Monsch, 1998; Small, Mobly, Jonsson Laukka, Jones, 
& Bäckman, 2003; Tierney, Yao, Kiss, & McDowell, 2005). The term “preclinical phase” 
has come to represent the period between disease onset and subsequent clinical 
diagnosis.  
The Preclinical Phase of Alzheimer Disease 
Alzheimer disease is characterized by intracellular changes that cause formation 
of neurofibrillary tangles and amyloid-rich plaques as well as neuron degeneration and 
                                                 
1 Economic cost provided by the Alzheimer’s Society of Canada (2006) for the year 2000, based 
on a projected estimate from Ostbye & Crosse (1994). 
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synaptic loss that gradually progress to a level that produces clinical symptoms (Bondi & 
Monsch, 1998; Desai & Grossberg, 2005; Munoz & Feldman, 2000). Katzman and 
Kawas (1994) presented a chronic disease model of AD in which risk factors such as 
family history, genetic markers (e.g., Apolipoprotein E or ApoE), head injury, coronary 
disease, and cerebrovascular conditions initiate the formation of plaques and tangles 
diffused throughout the cerebral cortex of potential AD patients. At this “latent stage” 
(Katzman & Kawas, 1994, p. 119) of the disease, corresponding cognitive and 
behavioural changes may be extremely subtle. When they experience promoting factors, 
such as advancing age, individuals in the latent phase may enter the “malignant phase” 
(Katzman & Kawas, p. 119) of AD, which is typified by chronic and progressive 
neuropathological changes and corresponding cognitive and functional decline that 
eventually leads to death. Based on this model, the “preclinical phase” of AD occurs at 
the transition between latent and malignant phases (Katzman & Kawas, 1994, p. 119).  
In recent years, there have been increasing developments in attempts to 
understand the precise disease manifestations in the preclinical stage of AD (Small, 
Fratiglioni, & Bäckman, 2001). Researchers have attempted to identify specific cognitive 
abilities that are affected in preclinical AD as well as determine the precise length of this 
stage. A growing body of evidence suggests that AD patients demonstrate a subtle or 
subthreshold level of impairment in various cognitive domains several years or even 
several decades before they meet clinical diagnosis for the condition (Arnaiz & Almkvist, 
2003; Smalll, Mobly, Jonsson Laukka, Jones, & Backman, 2003). 
Preclinical Cognitive Deficits 
Researchers who have focused on global indicators of cognitive functioning have 
reported lower performance on measures such as the Mini-mental State Examination 
(MMSE; Folstein, Folstein, & McHugh, 1975) and the Dementia Rating Scale (DRS; 
Mattis 1976) among individuals who progress to develop AD, as compared with those 
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who remain without dementia. For example, Small and his colleagues (2000) found 
baseline differences in the total score of the Swedish version of the MMSE between 
incident AD cases and healthy controls almost 7 years before eventual diagnosis. 
Similarly, in a prospective study, Troster and colleagues (1994) found that the DRS, a 
dementia staging measure, identified with 93% accuracy those among a group of at-risk 
individuals who progressed to develop AD over a 4- to 6-year time period.  
Studies that have focused on identifying predictors of progression to AD in 
specific cognitive areas have confirmed preclinical deficits in multiple domains. Tierney 
and her colleagues (1996) found attention deficits as measured by the Mental Control 
subset of the Wechsler Memory Scale – Revised (WMS-R; Wechsler 1987) reliably 
discriminated who among 124 memory-impaired non-demented patients developed AD 
at 2 year follow-up. In their examination of research on attention and executive functions 
in AD, Perry and Hodges (1999) reported that attention is the first non-memory domain 
to be affected in AD. In addition, they reviewed numerous studies indicating that 
individuals with early AD struggle with everyday as well as neuropsychological tasks that 
rely on executive functions.  
Jacobs and her colleagues (1995) found that language deficits characterized by 
word-finding and abstract verbal reasoning problems were associated with diagnosis of 
AD, on average 2.5 years later. Similarly, Flicker, Ferris, and Reisberg (1991) found 
older adults with clinically identified mild cognitive impairment who developed AD at 2 
year follow-up (n=23) demonstrated significantly poorer initial performance on language 
measures of object identification and object function recognition. In addition, Snowdon 
and his colleagues (1996), who analyzed the hand written autobiographies of 93 sisters 
who participated in the renowned Nun Study (Snowdon, Ostwald, & Kane, 1989), found 
that linguistic ability in early life was a reliable marker of AD in later years. They reported 
that low idea density and low grammatical complexity in early life autobiographies was 
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significantly associated with low neuropsychological performance, an average of 58 
years later. 
Investigations have also revealed preclinical deficits in areas of psychomotor 
speed and visuo-spatial skills. For example, using a logistic regression model, Masur 
and her colleagues (1994) found the Digit Symbol subtest of the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R; Wechsler, 1987), a task of visuomotor speed, 
emerged as a significant predictor of progression to dementia. In addition, using cluster 
analysis, Mitrushina, Uchiyama, and Satz (1995) found visuomotor constructional 
abilities to be one of the most affected domains of cognitive functioning in groups of 
individuals with early dementia.    
Although, collectively, the studies presented above suggest a lack of specificity in 
terms of preclinical cognitive deficits, it is noteworthy that a certain degree of memory 
deficit, in addition to declines in other cognitive areas, was reported for all AD patients. 
As such, a ubiquitous and pronounced cognitive feature of preclinical AD appears to be 
memory impairment. Differences in memory performance between AD patients and 
normal controls are seen in clinical tasks that assess various memory components (e.g., 
episodic, semantic, prospective, and working memory). In particular, numerous studies 
have shown that episodic memory deficits for both verbal (Linn et al., 1995; Tierney et 
al., 1996) and visual information (Small, Herlitz, Fratiglioni, Almkvist, & Bäckman, 1997) 
are prevalent in preclinical AD. In addition, episodic memory deficits in free recall (Linn 
et al, 1995; Grober, Lipton, Hall, & Crystal, 2000), cued recall (Bäckman & Small, 1998; 
Tuokko, Vernon-Wilkinson, Weir, & Beattie, 1991) and recognition (Bäckman, Small, & 
Fratiglioni, 2001; Fox, Warrington, Seiffer, Agnew, & Rossor, 1998) trials have been 
reported. In addition, AD patients also have been found to demonstrate compromised 
semantic memory abilities, characterized by a decline in fund of knowledge (Norton, 
Bondi, Salmon, & Goodglass, 1997), naming skills (Bayles & Tomoeda, 1983), and 
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verbal fluency (Butters, Granholm, Salmon, Grant, & Wolfe, 1987; Monsch et al., 1994; 
Salmon & Chan, 1999). A recent investigation by Spaan and her colleagues (2005) 
revealed that semantic and implicit memory problems apparent in preclinical dementia 
may explain some types of episodic memory deficits (e.g., compromised cued recall and 
recognition abilities) seen at this early stage.   
The episodic and semantic memory deficits seen in preclinical AD appears to 
reflect the underlying neuropathology seen at the earliest stages of the disease. 
Histopathological, morphological, and neuroimaging studies have revealed that the 
earliest brain changes in AD occur in the hippocampus and other medial temporal lobe 
structures. The medial temporal lobe area of the brain has been strongly implicated in 
episodic and certain semantic memory abilities (Foundas, Leonard, Mahoney, Agee, & 
Heilman, 1997; Jack et al., 1997; Mega et al., 2002). 
Preclinical Episodic Memory Deficits  
Episodic memory refers to the ability to learn and retain new information or 
autobiographical events that have been encoded relatively recently (Craik, 2000). In 
clinical settings, this type of memory is typically assessed with measures that involve the 
recall of presented materials such as word lists, stories, number sequences, or pictures. 
Bäckman and his colleagues (2001) investigated the course of preclinical episodic 
memory deficits in AD. Using data from the Kungsholmen Project, a Swedish population-
based longitudinal study, the researchers compared the episodic and short-term memory 
performance of people who developed AD (n=15) with individuals who were not 
demented (n=105) three to six years prior to their diagnosis. Episodic memory (i.e., free 
recall and recognition) was assessed using two word lists each containing 12 concrete 
words, and short-term memory was assessed with the Digit Span subtest of the WAIS-R 
(Wechsler, 1987). Bäckman et al. (2001) found that incident AD cases performed more 
poorly than their nondemented counterparts both three and six years before diagnosis 
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on both free recall and recognition measures of episodic memory. In contrast, there were 
no group differences with respect to short-term memory and there was no evidence of 
accelerated decline of episodic memory abilities in the incident AD group from six to 
three years before diagnosis.  
Similarly, in a prospective study of asymptomatic individuals at risk of autosomal 
dominant familial type AD, Fox et al. (1998) found that 10 out of 63 participants 
progressed to meet full criteria for possible or probable AD over a period of 6 years. 
When compared to participants who remained healthy, AD patients demonstrated poorer 
performance on a measure of verbal episodic memory (e.g., recognition test for words) 
at initial assessment. Fox and colleagues (1998) found no difference in performance 
between cases and controls on other neuropsychological measures of visual memory, 
naming, perception, arithmetic, spelling, psychomotor speed, and attention at initial 
assessment. In addition, for the 10 affected individuals, the mean time from initial 
assessment to first signs of clinical symptoms was approximately 3 years. 
In a prospective community study, Chen and colleagues (2001) found that the 
delayed recall score of a 10-item word list memory measure best discriminated between 
individuals who developed AD over a 1 ½ year period from those who remained 
nondemented. In addition, the authors found that among 16 neuropsychological tests 
examined, the combination of delayed recall score and Trail Making Test - Part B score, 
a measure of executive function (Reitan, 1955), had the highest accuracy in identifying 
individuals at the preclinical phase of AD. Similarly, in a recent study using the CSHA 
data set, Tierney and her colleagues (2005) found that the short delayed recall score on 
the Rey Auditory Verbal Learning Test (RAVLT; Taylor, 1959) was the best predictor of 
incident AD 5 years and 10 years prior to diagnosis. The authors found that it was not 
until 5 years prior to diagnosis that deficits in other cognitive abilities, including language 
problems (category fluency) became apparent.  
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Although the aforementioned and other (see also Linn et al., 1994, Masur, 
Sliwinski, Lipton, Blau, & Crystal, 1994) studies document episodic memory deficits, they 
traditionally use memory measures and procedures (e.g., word list recall and recognition 
paradigms, paired associate learning etc.) that may also be sensitive to deficits in other 
cognitive systems (e.g., attention, processing capacity, or executive functions). In other 
words, the deficits reported when using certain memory measures and procedures, may 
not reflect a pure deficit in the episodic memory system of AD patients. For example, 
Tuokko and her colleagues (1991) have argued that observed deficits may be attributed 
solely to memory only when measures that ensure appropriate encoding and processing 
of the to-be-learned material are used. The Buschke Cued Recall Task (BCRT; 
Buschke, 1984; modified by Tuokko & Crockett, 1989) is a memory measure that 
involves a search and selective reminding procedure to control encoding and retrieval. 
As such, the BCRT ensures reliable processing of information with minimal reliance on 
other cognitive processes and is deemed to be a relatively “pure” measure of episodic 
memory processes.  
The BCRT appears to be a sensitive measure for the early detection of AD. 
Using this measure in a prospective study of individuals referred to outpatient diagnostic 
clinic by community physicians, Tuokko and her colleagues (1991) found that 18 
participants who developed AD in the course of 12 to 18 months demonstrated poorer 
performance on free, cued and delayed recall at initial assessment when compared to 
27 participants whose diagnostic status remained unchanged over the same time period. 
In addition, the authors found that the retrieval score (i.e., total number of items freely 
recalled over 3 trials) was the best predictor of early AD. Although this study suggests 
that episodic memory difficulty may be the hallmark of early or possibly preclinical-AD, 
this finding is based on a relatively small sample of AD patients. The present series of 
studies aimed to extend this finding to a larger population-based Canadian sample. 
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Preclinical Semantic Memory Deficits 
The term semantic memory refers to the memory for general knowledge 
information or over-learned facts, and principles about objects, people, and events of the 
world (Farah & Grossman, 2000; Gazzaniga, Ivry, & Mangun, 1998) that are not 
dependent upon contextual cues for retrieval (Tulving, 1983). Unlike episodic memory, 
which is temporally specific, semantic memory is not linked to a specific learning event 
and is based on culturally shared knowledge (Hodges, Salmon, & Butters, 1992). 
Cognitive models of semantic memory (Collins & Loftus, 1975) assume that semantic 
knowledge is organized as a complex network of associated concepts. Concepts or 
objects that share many attributes (e.g., elephant, tiger, and hippopotamus) are more 
strongly linked within the network than are those that have few attributes in common 
(e.g., elephant, pencil, and tree). Attributes provide a means of categorizing objects and 
concepts into superordinate groups, while simultaneously distinguishing among 
exemplars that constitute a given category. Thus, elephant, tiger, and hippopotamus are 
all categorized as animals because of their shared attributes (e.g., living things, have 
four legs, etc.). At the same time, these animals can also be distinguished from each 
other based on other attributes such as their size, color, and shape (Salmon & Chan, 
1999). Semantic memory impairment can result from a lack of access to item-specific 
knowledge (i.e., retrieval of factual information), or from an actual deterioration of the 
representational network (Ober, 1999).  
Semantic memory is typically studied using clinical measures that assess factual 
knowledge (e.g., Information subtest of the WAIS-R; Wechsler, 1987), confrontational 
object naming (Boston Naming Test; Kaplan, Goodglass, & Weintraub, 1983), and 
verbal fluency. Studies have found that compared to age- and education-matched 
normal controls, individuals with mild to moderate dementia are impaired in their ability 
to recall generic factual and conceptual information (Norton et al., 1997; Weingartner, 
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Kawas, Rawlings, & Shapiro 1983), and in their ability to recognize and name objects 
(Bayles & Tomoeda, 1983). Lukatela and her colleagues (1998) found that AD patients 
made more naming errors than vascular dementia patients and healthy normal controls 
on the Boston Naming Test. These authors found that participants in all three groups 
tended to make more semantic than phonemic errors. However, qualitatively, AD 
patients made more superordinate errors (e.g., animal instead of beaver) compared to 
patients with vascular dementia.   
Another consistent finding in AD is that in the early stages of the disease, AD 
patients are impaired on verbal fluency tasks that require the time-limited generation of 
words beginning with a specific letter (e.g., phonemic fluency; Controlled Oral Word 
Association or FAS test, Spreen & Benton, 1977) or words that are exemplars of a 
specific semantic category, such as animals or fruit (e.g., category fluency; Animal 
Naming Test, Rosen 1980). However, studies that have compared the performance of 
AD patients on phonemic and category fluency measures directly have found that 
patients are impaired relative to normal controls on the semantic, but not the phonemic, 
fluency task (Butters et al., 1987; Monsch et al., 1994). Crossley and her colleagues 
(1997) confirmed this disproportionate reduction in category, as opposed to letter, 
fluency in a cohort of CSHA participants; mildly to moderately impaired AD patients were 
found to demonstrate greater impairments on category fluency (i.e., Animal Naming) 
than phonemic fluency (i.e., FAS test) compared to healthy older adults and other 
amnestic patients (e.g., Vascular Dementia).  
The difference in performance of AD patients between semantic and phonemic 
fluency tasks has been attributed to the greater demands category fluency places on the 
hierarchical structure of semantic knowledge (Butters et al., 1987), which is thought to 
deteriorate during the course of AD. From a neuropsychological perspective, Moscovitch 
(1995) has proposed that category fluency may be primarily mediated by the mesial 
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temporal lobe structures (i.e., the same structures that have been implicated in episodic 
memory), while letter fluency may be carried out by the frontal lobes. In the early stages 
of the disease, AD is known to affect the mesial temporal lobe structures with relative 
sparing in the frontal brain areas.  
While fluency tasks, and specifically the difference in performance between 
phonemic and semantic fluency tasks, are considered to be sensitive markers of AD, the 
use of these measures for detecting the disease is preclinical stages is not well 
established. There is some preliminary evidence that this specific pattern of semantic 
memory deficit is apparent in preclinical stages of AD. In a study designed to investigate 
patterns of cognitive decline over time in pre-symptomatic AD patients, Chen et al. 
(2001) reported that category fluency appears to be more sensitive to AD than phonemic 
fluency; the observed effect was small, but significant. As well, in a recent study using 
the CSHA dataset, Tierney and her colleagues (2005) found category  fluency 
(measured by Animal Naming test; Rosen 1980), in addition to delayed recall on a list 
learning measure and fund of knowledge to be significant predictors of incident AD over 
a five year period. In contrast, Fox et al. (1998) did not find differences in naming 
abilities (using the Graded Naming Test) between asymptomatic individuals at risk of 
developing familial AD who eventually went on to develop the disease and those who 
remained healthy. These authors suggest that semantic memory impairment may not be 
an early feature of familial AD. The present series of studies examine the diagnostic 
value of category fluency in relation to phonemic fluency at a preclinical stage of AD. 
Preclinical Psychomotor Speed Deficits 
Generalized decline in the speed of processing information has been suggested 
as the fundamental mechanism that accounts for age-related differences in cognitive 
performances (e.g., Salthouse, 1991; 1996). Perceptual speed tasks or simple paper-
and-pencil measures that require rapid processing of information (e.g., transcription of 
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numbers or symbols according to legend, same-different judgments about pairs of digits 
or symbols etc.) within a specified period of time have been used to study psychomotor 
speed in clinical and experimental settings. In aging studies, seniors have consistently 
demonstrated poorer performance on such measures compared to young adult 
counterparts (Park, 2000).  
There is emerging evidence that AD exacerbates the already compromised 
information processing ability in old age. Storandt and Hill (1989) found the WAIS-R Digit 
Symbol subtest, a sensitive measure of psychomotor speed, to be among the first tests 
affected in patients with mild AD. Similarly, using a logistic regression model, Masur and 
his colleagues (1994) found the WAIS-R Digit Symbol measure to be a significant 
indicator of progression to dementia. Consequently, the value of the WAIS-R Digit 
Symbol test in the preclinical detection of was investigated in the present series of 
studies. 
Overview of Present Studies 
Collectively, the four studies that constitute this document aim to examine the 
utility of a select group of neuropsychological measures from the Canadian Study of 
Health and Aging (CSHA) in distinguishing between individuals who progress to develop 
AD from those who remain healthy over a five year period. The CSHA, a population-
based study of dementia was conducted in three waves (CSHA-1, 1990-1991; CSHA-
2,1995-1996; CSHA-3, 2001-2002). The CSHA drew samples from distinct populations; 
English- or French- speaking Canadians who were assessed in their preferred language 
as well as individuals who were either residents of the community or institutions. The 
CSHA is described in detail in Appendix A. Different cohorts of participants from the 
CSHA were selected for inclusion in the present four investigations.  
The major goal in Studies 1 and 2 was to compare performances of AD patients 
and matched controls on select neuropsychological measures administered both at  
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CSHA-1 and CSHA-2. The objective was to investigate neuropsychological performance 
five years prior to clinical diagnosis. To this end, participants newly diagnosed with AD at 
CSHA-2 (i.e., incident cases) and a group of normal matched controls were followed 
retrospectively to CSHA-1; their baseline (CSHA-1) and reassessment (CSHA-2) 
performances on the neuropsychological measures were described and compared. 
Study 1 involved an English-speaking CSHA sample and Study 2 involved French-
speaking participants.  
The decision to focus on English and French-speaking participants separately 
was based on several factors. First, cultural, language, and educational differences have 
been recognized as confounding variables in the assessment of older adults of minority 
groups (Manly, Jacobs, & Mayeux, 1999). In light of this, there was a need to account for 
the significant differences in educational attainment between English- and French- 
speaking seniors in the CSHA sample. Second, Tuokko and her colleagues (1995) found 
significant differences in participation rates and diagnosis of dementia between English- 
and French-speaking participants. French-speaking participants declined to participate in 
the assessment at higher rates and were less likely than English-speaking participants to 
receive a dementia diagnosis. The precise reasons for these discrepancies remain 
unknown; however, it is possible that individuals at higher risk of dementia diagnosis 
were also more likely to decline study participation. Rather than attempt to control for 
sociocultural factors using statistical methods, the decision was made to conduct 
separate investigations using these distinct populations.  
Two main goals were addressed in Study 3, which is presented in a manuscript 
format within this document. First, this study aimed to examine the predictive value of 
the neuropsychological measures analyzed in Study 1. Specifically, Study 3 was 
conducted to determine which neuropsychological measures best distinguish individuals 
who develop AD from those who remain healthy over a five-year time period using a 
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larger sample of English-speaking CSHA participants. There was also an interest in 
determining to what extent demographic variables such as age, gender, and education 
contribute to the prediction of dementia. Second, Study 3 also aimed to validate how well 
the best predictors prognosticate clinical outcome in an independent sample of English-
speaking participants deemed to be at risk of developing dementia. To date, no other 
studies have validated how well an established set of predictors can prognosticate who 
amongst a group of individuals deemed to be at risk of developing dementia will 
eventually progress to develop the disease in a population-based sample. 
The main objective of Study 4 was identical to that of Study 3. Notably, Study 4 
was conducted to determine which neuropsychological measures best predict 
progression to AD. Study 4 involved French-speaking Canadians. Due to a variation in 
sample selection (see methods section in Study 4), this study did not include an actuarial 
validation component. A pictorial summary of all four studies is presented in Figure 1.  
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Study 1: Preclinical Neuropsychological Performance of English-Speaking 
Canadians with Alzheimer Disease 
Objectives 
A major purpose of Study 1 was to examine neuropsychological performance in 
preclinical AD. Specifically, cognitive performance was compared retrospectively 
between two groups of initially nondemented, English-speaking CSHA participants: 
clinical cases who subsequently developed AD and controls who remained 
nondemented over a five year period (i.e., between CSHA-1 and CSHA-2). The goal was 
to determine whether or not clinical cases demonstrate significantly lower 
neuropsychological performance compared to normal controls five years prior to 
diagnosis, when they are presumably in the preclinical stages of the disease. 
Specifically, the two groups were compared on a global measure of dementia (i.e., 3MS; 
Teng & Chui, 1987), an episodic memory task (i.e., BCRT; Buschke 1984 modified by 
Tuokko & Crockett, 1989), and a psychomotor speed measure (i.e., WAIS-R Digit 
Symbol; Wechsler, 1987). In addition, phonemic (Controlled Oral Word Fluency Test or 
FAS test; Spreen & Benton, 1977) and category fluency (Animal Naming; Rosen, 1980) 
measures were examined to determine if differential performance (i.e., poorer 
performance on category fluency compared to phonemic fluency) was evident. 
Based on previous research, the following hypotheses were made: First, 
individuals diagnosed with AD will show poorer performance than control participants on 
all neuropsychological measures at initial assessment (i.e., CSHA-1; five years prior to 
clinical diagnosis) and reassessment (i.e., CSHA-2; time of diagnosis). Second, the 
deterioration in performance between the two assessment times will be greater for those 
diagnosed with AD than healthy controls. Third, those with AD will demonstrate worse 
performance on the category fluency task relative to the phonemic fluency task, 
compared to healthy controls, at initial assessment and reassessment.  
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Methods 
 Study Design and Participants. See Appendix A for a detailed description of the 
CSHA. In the present study, the neuropsychological performance of AD participants and 
healthy older adults who were assessed in English at CSHA-1 and CSHA-2 was 
analyzed. The CSHA-2 identified 326 (98 males and 228 females) incident cases of AD; 
twenty-nine individuals from this sample completed neuropsychological assessment in 
English at both CSHA-1 and CSHA-2. The neuropsychological performance of these 29 
individuals (19 with probable AD and 10 with possible AD) was compared to age-, 
gender-, and education-matched healthy adults. Healthy controls were selected from a 
group of 181 English-speaking participants who were assessed to be cognitively normal 
(i.e., no cognitive impairment; NCI) at CSHA-2 and for whom neuropsychological data 
were available at both CSHA-1 and CSHA-2. The participant matching process involved 
selecting, from the NCI group, participants who were first of the same gender and who 
were within 5 years in age and educational level as each of the 29 clinical participants.  
Demographic and background characteristics of incident AD cases and healthy 
controls are presented in Table 1. There were 7 males and 22 females in each group. 
Univariate analyses indicated that the matching process was successful; there was no 
significant age- or education- differences between the clinical and control groups (age, 
t(56) = -.03, p < .98; education, t(56) = .52, p < .61). In addition, as expected no 
participants in the control group were diagnosed with dementia at CSHA-1. In contrast, 
significantly more participants in the clinical group were classified as having clinical 
impairment but no dementia (CIND) at CSHA-1 than were individuals in the control 
group (16 vs 4, respectively, χ2 (1, N =58) = 10.99, p < .01) suggesting that more 
individuals in the clinical group had subthreshold levels of cognitive impairment five 
years prior to clinical diagnosis.  
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Table 1 
Demographic Summary For Clinical and Control Group 
  
Clinical Group 
 
Control Group 
 
Variable 
 
M (SD) 
 
M (SD) 
 
86.7 (5.1) 
 
9.7 (4.2) 
 
 
86.7 (5.0) 
 
10.3 (4.4)  
  
 
N 
 
N 
 
Age at CSHA-2  
 
Education 
 
 
 
 
Gender  
     Male 
     Female 
 
Residence at CSHA-2 
     Community 
     Institution 
 
CSHA-1 Diagnosis 
     NCI 
     CIND 
 
 
7 
22 
 
 
18 
11 
 
 
13 
16 
 
 
7 
22 
 
 
25 
4 
 
 
25 
4 
NCI = No Cognitive Impairment; CIND = Cognitive Impairment No Dementia 
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Measures. The neuropsychological assessment component of the CSHA 
included 12 measures designed to assess different domains of cognitive functions 
including memory, language ability, judgment, abstract thinking, and processing speed  
From the test battery, a group of neuropsychological measures assessing three domains 
of cognitive functions (i.e., episodic memory, verbal fluency/semantic memory, and 
psychomotor speed) were chosen for inclusion in the present analyses. As well, 
performance on the 3MS, a global indicator of dementia, was investigated. A description 
of the measures and the specific scores that were examined are presented in Table 2.  
The BCRT, FAS, Animal Naming, and Digit Symbol tests were selected for 
several reasons. First, they were administered in an unmodified manner in all three 
waves of the CSHA. This was important because collectively the four studies described 
in this document span all three waves of the CSHA and there was a need to maintain 
consistency for comparative purposes. Second, the cognitive domains assessed by the 
selected measures are typically reported to decline in dementia. As such, the interest 
was to see how participants who develop AD perform on these domains at a preclinical 
stage. Third, there was a specific interest in investigating performance on the BCRT test, 
which has previously been described as a relatively “pure” form of memory test than 
other list learning measures (Tuokko, Vernon-Wilkinson, Weir, & Beattie 1991). As well, 
there was a specific interest in examining the differential performance on phonemic vs 
category fluency measures in preclinical AD. It is noteworthy that the Digit Symbol test 
was added to the analyses, to further understand the neuropsychological markers of AD. 
Performance on the Digit Symbol, a measure that assesses speeded psychomotor 
performance, including motor persistence, sustained attention, response speed, and 
visuomotor coordination, is presumed to be unaffected by memory or learning in healthy 
older adults.  
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Table 2 
Description of measures and scores used in the analysis 
Global Indicator:                    3MS 
A brief screening measure for cognitive impairment consisting of items assessing 
orientation, attention/concentration, language, constructional ability, and memory  
 
 Score 
 
Total number of item completed accurately (max = 100) 
 
Episodic Memory:                  Buschke Cued Recall Test (BCRT) 
Participants are required to identify 12 common items (e.g., bed) presented pictorially; 
each item’s semantic category cue (e.g., furniture) is given. Following a distractor task, 
participants are asked to freely recall items and are provided with semantic category 
cues to prompt for missed items. A total of three free and cued recall trials are 
administered. A final free and cued recall trial is administered after a 15-min time delay. 
           
Retrieval score 
 
           
Acquisition score 
 
           
Delayed free recall 
score 
 
           
 Retention score 
 
Total number of item recalled freely (i.e., without cuing) over three 
learning trials (max = 36) 
 
Total number of items recalled freely and with cuing over three 
learning trials (max = 36) 
 
Total number of items recalled freely on the delayed recall trial 
(max = 12) 
 
 
Total number of items recalled freely and with cuing on the delayed 
recall trial (max = 12) 
  
 
Verbal Fluency:                      Phonemic Fluency  (FAS Test) 
Oral generation of words beginning with letters F, A, and S in three 60-sec trials 
 
                                                 Category Fluency (Animal Naming) 
Oral generation of animal names in one 60-sec trial 
 
 FAS Score 
      
Animal Naming  
Score          
 
Total number of words generated over three trials  
 
Total number of animal names generated over one trial 
 
Psychomotor Task:                 Digit Symbol (WAIS-R) 
Participants are requested to transcribe symbols according to a specified number-
symbol legend in a 90-sec trial  
  
 Score 
 
Total number correctly paired number and symbols 
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Statistical Analysis. The aim of this study was to investigate longitudinal changes 
in cognitive performance for incident AD cases and healthy controls between initial 
assessment (CSHA-1) and five year follow-up (CSHA-2). Separate 2(Group: Clinical vs. 
Control) X 2(Time: CSHA-1 vs. CSHA-2) repeated measures ANOVAs, with group as a 
between subject variable and time as a within-subject repeated variable, were conducted 
for each neuropsychological measure. To further understand resultant interaction effects 
from these ANOVAs, post hoc analyses in the form of separate paired sample t-tests 
were conducted to examine mean-level differences between clinical and control groups 
at initial assessment and reassessment. In addition, performance on the phonemic 
fluency and category fluency measures were directly compared first by converting raw 
scores to z-scores, expressed in standard deviations from the mean of an independent 
sample of 105 English-speaking health older adults who had fluency measures data 
available at both CSHA-1 and CSHA-2. This independent sample comprised of a 
subgroup of participants from the 181 individuals who were assessed to be cognitively 
normal at CSHA-2 and who were initially used in the participant matching process, as 
described above. It is noteworthy that the 29 controls who were matched to clinical 
participants were excluded from the fluency measures standardization sample to ensure 
independence of observation (i.e., to ensure that scores will not be counted twice).     
Phonemic and category fluency tasks were directly compared with a 2 (Group: Clinical 
vs Control) X 2 (Task: FAS vs Animal Naming) X 2 (Time: CSHA-1 vs CSHA-2) repeated 
measures ANOVA, with group as a between-subjects variable and task and time as 
within-subject repeated variables. ANOVA tables for all neuropsychological measures 
analyses are presented in Appendix B. 
Results 
Global Indicator of Cognition. The 3MS performance of the participants at CSHA-
1 and CSHA-2 are presented in Table 3. A significant main effect of group was found, 
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Table 3 
3MS Performance for Clinical and Control Group Participants at CSHA-1 and  
 
CSHA-2   
  
Clinical Group 
 
 
Control Group 
  
M 
 
SD 
 
M 
 
SD 
 
CSHA-1 
 
CSHA-2 
 
77.7 
 
62.8 
 
9.8 
 
9.4 
 
88.2 
 
87.1 
 
7.8 
 
9.6 
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with the clinical group performing more poorly than the control group at both initial- and 
re-assessment, F(1, 56) =  63.96, p < .001. In addition, there was a significant main 
effect of time. Both groups of participants evidenced a decline in 3MS performance 
between CSHA-1 and CSHA-2, F(1, 56) = 59.14, p < .001. These main effects of group 
and time were qualified by a significant interaction effect between the variables, with the 
clinical group showing greater deterioration in performance between the two  
administrations relative to the control group, F(1, 56) = 43.61, p < .001. This interaction 
effect was confirmed by post-hoc analyses; paired sample t-tests revealed a significant 
change in performance between CSHA-1 and CSHA-2 for the clinical group, but not the 
control group (clinical group, t(28) = 6.27, p < .001; control group, t(28) = 1.08, p = .29).  
Episodic Memory Measure (BCRT). Episodic memory performance (i.e., BCRT 
scores) of clinical and control participants at initial assessment and follow-up is 
presented in Table 4. Separate repeated measures ANOVAs revealed a significant main 
effect of diagnostic group for all four BCRT dependent variables, indicating the poorer 
performance of the clinical group compared to the control group with respect to the 
retrieval, acquisition, delayed free recall, and retention of BCRT items at both initial- and 
re-assessment (F(1,54) = 63.29, p < .001 for retrieval; F(1,54) = 20.88, p < .001 for 
acquisition; F(1,55) = 48.65, p < .001 for delayed free recall; F(1,55) = 18.81, p < .001 
for retention). Although there was a significant main effect of time for all variables 
(F(1,54) = 45.25, p < .001 for retrieval; F(1,54) = 21.87, p < .001 for acquisition; F(1,55) 
= 33.86, p < .001 for delayed free recall; F(1,55) = 22.62, p < .001) for retention, 
reflecting a decline in performance between CSHA-1 and CSHA-2, this was qualified by 
significant Group X Time interactions (F(1,54) = 12.34, p < .01 for retrieval; F(1,54) = 
18.20, p < .001 for acquisition; F(1,55) = 18.02, p < .001 for delayed free recall; F(1,55) 
= 20.34, p < .001 for retention). Post-hoc analyses revealed that the change in 
performance between initial and reassessment was significantly greater for AD 
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Table 4 
BCRT Performance of Clinical and Control Group Participants at CSHA-1 and  
 
CSHA-2 
  
Clinical Group 
 
Control Group 
 
BCRT Variable 
 
M 
 
SD 
 
N 
 
M 
 
SD 
 
n 
 
Retrieval  
 
     CSHA-1 
 
     CSHA-2 
 
Acquisition 
 
     CSHA-1 
 
     CSHA-2 
 
Delayed Free Recall 
 
     CSHA-1 
 
     CSHA-2 
 
Retention 
 
     CSHA-1 
 
     CSHA-2      
 
 
 
19.5 
 
11.0 
 
 
 
34.0 
 
27.8 
 
 
 
7.3 
 
3.7 
 
 
 
11.3 
 
8.7 
 
 
 
7.0 
 
8.6 
 
 
 
4.6 
 
8.0 
 
 
 
3.0 
 
3.6 
 
 
 
1.5 
 
3.6 
 
 
 
28 
 
28 
 
 
 
28 
 
28 
 
 
 
29 
 
29 
 
 
 
29 
 
29 
 
 
 
28.2 
 
25.5 
 
 
 
35.8 
 
35.5 
 
 
 
10.4 
 
9.8 
 
 
 
11.9 
 
11.9 
 
 
 
4.0 
 
4.5 
 
 
 
0.7 
 
1.7 
 
 
 
1.8 
 
2.6 
 
 
 
0.3 
 
0.6 
 
 
 
28 
 
28 
 
 
 
28 
 
28 
 
 
 
28 
 
28 
 
 
 
28 
 
28 
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 participants than healthy controls for the acquisition (clinical group, t(27) = 4.61, p < 
.001; control group, t(27) = .85, p = .40), delayed free recall (clinical group, t(28) = 6.03, 
p<.001; control group, t(27) = 1.47 p = .15), and retention variables (clinical group, t(28) 
= 4.77, p < .001; control group, t(27) = .81, p = .42). It is noteworthy that although the  
raw scores indicate that AD participants demonstrated a greater deterioration of 
performance over time on the BCRT retrieval measure, according to post hoc analyses, 
the control group also demonstrated significant declines between the two assessment 
periods. This likely represents the normal-age related decline in episodic memory 
documented in neuropsychological studies (Craik, 2000).  
  Verbal Fluency Measures (FAS test and Animal Naming). Table 5 shows the 
phonemic (FAS) and category (Animal Naming) fluency scores for clinical and control 
groups at CSHA-1 and CSHA-2. Separate repeated measures ANOVA’s revealed  
significant main effects of diagnostic group and time that were qualified by a significant 
interaction effect between these variables for both fluency measures. Clinical group 
participants produced significantly fewer words on FAS and Animal Naming tests 
compared to control group participants at initial- and re- assessment (F(1,51) = 14.58, p 
< .001 for FAS; F(1,55) = 26.76, p < .001 for Animal Naming). Although a main effect for 
time suggested that performance of both groups of participants on the two fluency 
measures declined between assessment periods (F(1,51) = 17.74, p < .001 for FAS; 
F(1,55) = 11.11, p < .01 for Animal Naming), this was qualified by a Diagnostic Group X 
Time interaction. AD participants demonstrated a greater deterioration of performance 
over time on the fluency measures compared to healthy older adults (F(1,51) = 13.71, p 
< .01 for FAS; F(1,55) = 9.10, p < .01 for Animal Naming). This pattern of performance 
was confirmed with post-hoc analyses; paired sample t-tests revealed a significant 
change in performance between CSHA-1 and CSHA-2 for the clinical group, but not the 
control group for the phonemic (clinical group, t(26) = 5.12, p <. 001;  
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Table 5 
Phonemic and Category Fluency Performance of Clinical and Control Group  
 
Participants at CSHA-1 and CSHA-2 
  
Clinical Group 
 
 
Control Group 
Fluency Measures 
 
M SD n M SD n 
 
Phonemic Fluency   
(FAS test) 
  
     CSHA-1 
 
     CSHA-2 
 
Category Fluency 
(Animal Naming Test) 
 
     CSHA-1 
 
     CSHA-2 
 
 
 
 
23.5 
 
15.1 
 
 
 
 
11.7 
 
8.3 
 
 
 
 
  
13.1 
 
9.6 
 
 
 
 
3.3 
 
3.2 
 
 
 
 
27 
 
27 
 
 
 
 
28 
 
28 
 
 
 
 
31.6 
 
31.0 
 
 
 
 
14.7 
 
14.6 
 
 
 
 
13.2 
 
12.2 
 
 
 
 
5.0 
 
4.0 
 
 
 
 
26 
 
26 
 
 
 
 
29 
 
29 
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control group, t(25) = .40, p =.70) and category fluency variables (clinical group, t(27) = 
5.42, p < .001; control group, t(28) = .20, p = .85).  
Letter and category fluency scores were directly compared by converting each 
participant’s score on both measures to standard scores (z scores), expressed in  
standard deviations from the mean of an independent sample of healthy older adults 
from CSHA-2 (n=150; see Fig 2). A 2 (Group: Clinical vs Control) X 2 (Task: FAS vs  
Animal Naming) X 2 (Time: CSHA-1 vs CSHA-2) repeated measures AVOVA was 
performed, with diagnostic group as a between-subjects variable and task and time as 
within-subject repeated variables. This analysis resulted in a significant main effect of 
group, F(1,50) = 23.47, p < .001 and time, F(1,50) = 21.84, p < .001, which were 
qualified by a significant interaction effect, F(1, 50) = 14.75, p < .001. As reported above, 
AD participants’ performance on both the FAS and Animal Naming tests declined  
significantly over time compared to the control participants. The main effects for task 
type (FAS vs Animal Naming) and interaction effects among the three factors were not 
found to be significant. 
Psychomotor Performance (WAIS-R Digit Symbol Test). The means and 
standard deviations for the WAIS-R Digit Symbol test are presented in Table 6. Results 
were analyzed using a 2 (Group: Clinical vs Control) X 2 (Time: CSHA-1 vs CSHA-2) 
repeated measures ANOVA, with group as a between-subject variable and time as a 
within-subject repeated variable. A significant main effect of group was found, 
suggesting that the participants diagnosed with AD at CSHA-2 performed significantly 
worse on the WAIS-R Digit Symbol test both at initial- and re-assessment relative to 
healthy older adults, F(1,41) = 13.07, p < .01. However, both groups of participants 
evidenced a decline in performance between initial- and re-assessment as implicated by 
a significant main effect of time, F(1, 41) = 28.29, p < .001. There was no significant 
interaction between the variables. 
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Fig. 2: Standard scores of clinical and control group participants on FAS and 
Animal Naming tests  
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Table 6 
Digit Symbol Test Performance of Clinical and Control Group Participants at  
 
CSHA-1 and CSHA-2 
  
Clinical Group 
 
Control Group 
 
 
 
M 
 
SD 
 
n 
 
M 
 
SD 
 
N 
 
Digit Symbol Test 
 
     CSHA-1 
 
     CSHA-2 
 
 
 
21.3 
 
14.1 
 
 
 
6.5 
 
8.2 
 
 
 
19 
 
19 
 
 
 
29.9 
 
25.5 
 
 
 
11.0 
 
11.3 
 
 
 
24 
 
24 
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Discussion  
This study investigated the cognitive performance of individuals with incident AD, 
five years prior to clinical diagnosis. The present results indicate that cognitive changes 
can be detected when AD participants are at the preclinical phase of the disease, with 
compromised performance evident on a global indicator of cognition, as well as on 
measures of episodic memory, verbal fluency, and psychomotor skills. Individuals 
diagnosed with AD at CSHA-2 demonstrated decline in performance between initial 
assessment and five year follow-up on all neuropsychological measures. In addition, 
declines in performance for healthy controls were also evident on the episodic memory 
free retrieval score and on the psychomotor speed measure, suggesting that these tasks 
are also sensitive to normal aging processes. The overall results of the present study 
replicate and expand past findings that the preclinical stage of AD is characterized by  
cognitive impairment in multiple cognitive domains, including episodic memory, 
particularly after a long time delay.   
An important purpose of the present study was to determine how individuals with 
preclinical AD perform on the BCRT, an episodic memory measure that controls 
encoding by means of search and selective reminding procedures and facilitates 
retrieval with effective categorical cues. Tuokko and her colleages (1991) have 
previously argued that the rigorous coordination of encoding and retrieval procedures of 
the BCRT is necessary to ensure that appropriate processing of to-be-remembered 
material is carried out and that observed deficits are solely attributable to memory 
capacity and not to attentional or other cognitive factors.  Tuokko et al. (1991) also found 
that 18 out of 45 participants, who were diagnosed with probable or possible AD at 12 to 
18 months following initial assessment, performed poorly compared to those who 
remained nondemented on the BCRT measures of retrieval, acquisition, and retention. 
The results of the present study confirm this finding with a population-based sample and 
 38
a longer reassessment period. The results show that individuals who were diagnosed 
with probable or possible AD demonstrated poorer performance on all BCRT variables 
(i.e., retrieval, acquisition, retention, and delayed free recall) at time of diagnosis and five 
years prior. In addition, clinical participants showed a greater deterioration in 
performance from initial to follow-up assessment compared to their healthy counterparts 
on acquisition, retention, and delayed recall. The overall pattern of performance 
suggests that individuals at the preclinical stage of AD may not benefit from cues, and 
extensive encoding and retrieval strategies, to the same extent as healthy seniors.  
 An incidental observation made by Tuokko and her colleages (1991) is that 
individuals with mild AD and healthy counterparts performed comparably well on the 
delayed recall trial of the BCRT. The present study did not support this finding. 
Participants with incident AD at CSHA-2 demonstrated lower performance on the 
delayed recall trial of the BCRT, compared to their healthy counterparts at time of 
diagnosis and five years prior. The difference in results between the two studies may be 
related to methodological variations including the larger community based sample size 
used in the present investigation. In addition, it is noteworthy that participants in the 
current study were on average at least 10 to15 years older than the participants involved 
in Tuokko et al.’s investigation. Given that age is significantly related to episodic memory 
performance (Craik, 2000), the sample age differences could also account for the 
discrepancy in results.  Alternatively, it is noteworthy that the present results are 
consistent with other investigations that indicate delayed memory measures have 
reliably differentiated individuals who progress to develop AD from those who remain 
healthy at a preclinical stage (Chen et al., 2001; Linn et al., 1995; Saxton et al., 2004).  
A second purpose of the present investigation was to determine if differential 
performance on phonemic vs. category fluency (FAS > Animal Naming) measures is a 
consistent feature of preclinical AD. Investigations that have compared directly the 
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performance of AD patients on phonemic and category fluency measures have found 
that AD patients are impaired relative to normal controls on the category (i.e., semantic), 
but not the phonemic fluency task (Butters, Granholm, Salmon, Grant, & Wolfe, 1987; 
Crossley, D’Arcy, & Rawson, 1997; Chen et al., 2001; Monsch et al., 1994; Salmon, 
Heindel, & Lange, 1999). The present results were inconsistent with these findings. 
Relative to healthy controls, AD participants in the current sample did not demonstrate 
poorer performance on the Animal Naming task compared to the FAS test. While there 
are investigations (see Fox, Warrington, Seiffer, Agnew, & Rossor, 1998) that suggest 
that semantic memory problems may not be a consistent marker of preclinical AD, in the 
present case, the relatively small sample size might have limited the ability to detect a 
statistical difference in performance on the two fluency measures.   
The present investigation found that compared to healthy seniors, participants 
with incident AD demonstrated compromised performance on the WAIS-R Digit symbol 
measure both at time of diagnosis and five years prior. Interestingly, unlike performance 
on the episodic and verbal fluency measures, both groups of participants demonstrated 
a significant decline in performance between the two assessment periods. This finding is 
consistent with previous studies that have suggested that response slowing or changes 
in speed of information processing is associated with normal aging (Lezak, 1995; 
Salthouse, 1996) and is more pronounced in individuals with AD (Crossley, Hiscock, & 
Foreman, 2004; Storandt & Hill, 1989).   
Overall, the results of this study indicate that individuals in the preclinical stages 
of AD demonstrate compromised performance in several cognitive domains, including 
episodic memory, verbal fluency, and psychomotor speed. The current study has several 
advantages. First, the study cohort was selected from a larger population-based sample. 
This procedure minimizes the selection bias associated with convenience samples, such 
as senior volunteers or hospital patients, and allows for greater generalizability of 
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results. In addition, this study accounts for the cognitive changes of normal aging by 
including a group of demographically matched healthy controls. This study also included 
the assessment of cognitive functions at two points in time, allowing for longitudinal 
comparisons, minimizing potential problems associated with a single assessment period.  
There are also several limitations to this study. First, because of the specific 
interest in evaluating performance between CSHA-1 and CSHA-2 on select 
neuropsychological measures, the study involved a relatively small sample size. This 
may have led to reduced power in detecting performance differences between clinical 
and control participants on certain measures (e.g., verbal fluency: FAS vs Animal 
Naming). To address this potential problem of reduced power, a different sample 
selection procedure was adopted in a follow-up study, which examined the predictive 
power of the select neuropsychological measures in distinguishing individuals who 
progress to develop AD from those who remained healthy over a 5 year period (see 
Study 3). In addition, the participant sample in the present investigation consisted of 
relatively older English-speaking Canadians. Consequently, the extent to which the 
results can be generalized to younger seniors may be limited. In addition, the extent to 
which the current results can be extended to seniors from diverse populations remains to 
be determined and was the focus of the next investigation in the current series of studies 
(see Study 2).  
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Study 2: Preclinical Neuropsychological Performance of French-Speaking 
Canadians with Alzheimer Disease 
Introduction 
 Most research in the area of geriatric neuropsychology has involved seniors of 
dominant cultural identities who are routinely assessed in English. However, there is 
increasing evidence that cultural and language differences affect cognitive performance, 
and consequently diagnostic outcomes. This, in addition to other methodological 
variations (e.g., definitions of ethnicity, sampling methods, reliability of test translations 
etc.) between studies, has led to a range of different estimations in the prevalence of 
dementia across cultural and language groups in North America (Manly, Jacobs, & 
Mayeux, 1999). However, the finding of age-related increase in the rates of Alzheimer 
Disease (AD) is ubiquitous. This, coupled with the general population aging trends, 
suggests that health care professionals are increasingly faced with the challenge of 
accurately diagnosing dementia in seniors from a variety of cultural and language 
groups. Therefore, there is a growing need to expand our knowledge of 
neuropsychological performance in diverse populations. 
North American research in the area of cross- and intra-cultural geriatric 
neuropsychology has mainly focused on Hispanics, African Americans, Asians, and 
Native Americans residing in the United States. In addition, only a handful of studies 
involve clinical populations and are conducted in the native language of the participants. 
Collectively, however, studies have found differences in performances on global 
screening measures and in specific domains of neuropsychological functions when 
cultural groups are matched on sociodemographic factors such as age, gender, and 
levels of education. Bohnstedt and his colleagues (1994) found that the Mini-Mental 
State Examination (MMSE, Folstein, Folstein, & McHugh, 1975), a global screening 
measure of dementia, over-diagnosed African American and Hispanic patients 
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compared to Caucasians when the traditional cut-off score of 23 was used and when the 
instrument was administered in English, even after adjusting for education between the 
groups. In another investigation, Marshall and her colleagues (1997) found that only 15 
out of the 26 items of the MMSE provide unbiased measurement across groups of 
English- and Spanish-speaking individuals who were assessed in their native languages, 
and a separate group of Spanish-speaking individuals assessed in English. 
Specific research investigating neuropsychological measures administered in 
languages other than English has mainly involved Spanish-speaking cultural groups in 
North America. In their community-based study of non-demented, demographically-
matched English- and Spanish-speaking seniors who were assessed in their native 
language, Jacobs and her colleages (1997) found significant group differences on 
several neuropsychological measures. Spanish-speaking elders scored significantly 
lower than their English-speaking counterparts on measures of category fluency (i.e., 
naming exemplars of animal, food, and clothing), nonverbal abstraction (i.e., identifying 
similarities and differences from the Dementia Rating Scale, Mattis, 1976), visual 
recognition memory (i.e., Benton Visual Recognition Test, Benton, 1955), visual 
perceptual skills (i.e., Benton Visual Recognition Test, matching, Benton, 1955) and 
auditory comprehension (i.e., Complex Ideation Material subtest from the Boston 
Diagnostic Aphasia Examination, Goodglass & Kaplan, 1983). Comparable performance 
between groups was found on the remaining 14 measures of the neuropsychological 
battery, including those that assessed auditory memory, visual- constructional abilities, 
and repetition.  
Researchers have also found that ethnic differences in neuropsychological 
performances may be influenced by the inherent differences in linguistic factors of native 
languages.  For example, the fact that the Spanish language consists of less words 
beginning with the letters “F”, “A”, and “S” compared to the English language has been 
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cited as the potential reason for the poor performance of Spanish-speaking healthy 
seniors on the FAS, verbal fluency test (Loewenstein, Arguelles, Arguelles, & Linn-
Fuentes, 1994). In the same way, Kempler and his colleagues (1998) found that 
Vietnemese-speaking individuals generated significantly more animal names on a 
category fluency task compared to Spanish-speaking individuals of equivalent 
educational background. The authors attributed this difference to the finding that 
Vietnamese animal names are mainly monosyllabic while Spanish animal names consist 
of multiple syllables; the better performance of Vietnamese participants was attributed to 
the differences in word length of animal names between Vietnamese and Spanish 
languages, since word length is a parameter that is known to affect word production.  
In an intra-cultural investigation using cohorts of Swedish-speaking participants 
from The Kungsholmen Project, a longitudinal, population-based study of dementia 
conducted in Sweden, Small and his colleagues (2000) found significant differences 
between individuals who progressed to develop AD from those who remained healthy 
over a six year period on the Swedish version of the MMSE. Particularly, AD patients 
performed more poorly on the orientation to time, and the delayed word recall items of 
the MMSE. In another investigation of participants from the Kungsholmen Project 
epidemiological study, Bäckman and his colleagues (2001) found that incident AD cases 
performed more poorly than their nondemented counterparts both three and six years 
before diagnosis on both free recall and recognition measures of episodic memory. In 
contrast, there were no group differences with respect to immediate memory and there 
was no evidence of accelerated decline of episodic memory abilities in the incident AD 
group from six to three years before diagnosis. 
It is noteworthy that some investigations have indeed failed to find discrepancies 
in test performance among cultural and language groups after participants were 
matched on sociodemographic variables. For example, in a recent study, Whyte and her 
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colleagues (2005) found the CERAD neuropsychological battery (Morris et al., 1989) to 
be an efficient cognitive screening assessment measure for English-speaking Native 
Americans. In comparing the performance of 40 Native American seniors and 
demographically matched Caucasians diagnosed with AD, Whyte et al. (2005) did not 
find statistically significant differences between the two groups on any of the CERAD 
measures. Interestingly, when compared to the Caucasian group, Native Americans 
were found to demonstrate slightly better, albeit not statistically significant, performance 
on most CERAD measures, with the exception of the constructional praxis test that 
assessed drawing of geometrical figures. Other investigations have involved 
comparatively smaller sample groups. For example, Ripich, Carpenter, and Ziol (1997) 
compared 11 African Americans and 32 Whites with AD and reported no significant 
ethnic differences on measures of naming, picture vocabulary, verbal abstraction, verbal 
list learning, and pragmatic language.  
The heterogeneity of findings in previous studies suggests that language and 
cultural differences can impact cognitive performance and not always in the expected 
direction. Although the source of immigration to Canada has changed over the years, 
with increasingly more people moving from non-European countries, next to English, 
French continues to be the most predominant language spoken in households (Statistics 
Canada, 2002). In addition, with their unique immigration and cultural histories, there is 
little reason to question the distinct identity of the French-speaking peoples of Canada. 
As is the case with other cultural groups, the population of French-speaking seniors in 
Canada is expected to grow exponentially in the future. Given that previous studies have 
implicated language as a factor that can influence cognitive performance and potentially 
lead to variable diagnosis of degenerative conditions such as AD and other dementias, 
there was an interest in understanding the neuropsychological performance of French-
speaking Canadians.     
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The Canadian Study of Health and Aging (CSHA; described in Appendix 1) 
provided a unique opportunity to examine preclinical and longitudinal cognitive 
performance of French-speaking Canadians across the country.  A total of 1879 
participants were administered the neuropsychological battery of measures at the first 
wave of the study (CSHA-1). Of these individuals, 447 were assessed in their preferred 
language of French and surviving participants were subsequently followed up at 
approximately five year intervals for CSHA-2 and CSHA-3. The present investigation 
examined the preclinical and longitudinal performance of a cohort of French-speaking 
CSHA participants on select neuropsychological measures.  
Conceptually, the goals of the present study are identical to those of Study 1, 
described above. Specifically, this study compares performance of French-speaking 
participants diagnosed with AD at CSHA-2 and matched normal controls on 3MS, BCRT, 
FAS test, Animal Naming, and WAIS-R Digit Symbol measures between CSHA-1 and 
CSHA-2 to determine if differences are detectable at initial assessment (i.e., five years 
prior to AD diagnosis). In addition, this study examines if differential performance in 
phonemic and category fluency measures are evident in a French-speaking population. 
It is noteworthy that the selected measures were available in French versions and this 
was one of reasons they were initially included in the CSHA neuropsychological battery 
(Tuokko, Kristjansson, & Miller, 1995). In addition, it is also notable that, overall, the core 
battery was equally well tolerated by French- and English-speaking participants (Tuokko 
et al., 1995).     
The rational to study the cognitive performance of English and French-speaking 
Canadians separately was multifaceted. First and foremost, there was an aspiration to 
address the growing need for neuropsychological studies with non-English speaking 
cultural groups, to examine if language-related cognitive differences are evident in a 
Canadian population. Second, there was a need to consider the demographic and socio-
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cultural differences between participants who were administered the CSHA 
neuropsychological battery in English and in French. Tuokko and her colleagues (1995) 
found that community-dwelling, French-speaking participants refused to participate in the 
neuropsychological assessment at higher rates and were less likely than English-
speaking participants to receive a diagnosis of dementia. Moreover, there were 
significant differences in demographic status, including educational attainment between 
the English- and French-speaking CSHA samples. Tuokko and her colleagues report 
that French speaking participants who participated in the CSHA neuropsychological 
assessment component, on average, had about three years less education than their 
English-speaking counterparts. Interestingly, the assumption that lower education leads 
to higher rates of dementia diagnosis did not hold true for the French-speaking sample in 
the CSHA. Rather than attempt to control for sociocultural factors using statistical 
methods, the decision was made to conduct two separate investigations using these 
distinct populations. 
Methods 
 Study Design and Participants. Of the 326 (98 males and 228 females) 
individuals who received an incident diagnosis at CSHA-2, 12 individuals completed 
neuropsychological assessment battery in French at both CSHA-1 and CSHA-2. The 
neuropsychological performance of these 12 individuals (7 with probable AD and 5 with 
possible AD) were compared to 11 age-, gender-, and education-matched healthy 
adults. Healthy controls were selected from a group of 63 French-speaking participants 
who were assessed to be cognitively normal (i.e., no cognitive impairment) at CSHA-2 
and for whom neuropsychological data were available at both CSHA-1 and CSHA-2. A 
suitable match for one AD female participant in terms of gender and education was 
unavailable; consequently, this resulted in the unequal sample size, with one less 
participant in the control group, as reported above.  
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Details of demographic and background characteristics of incident AD cases and 
healthy controls are presented in Table 7. There were 7 males and 5 females in the 
clinical group and 7 males and 4 females in the control group. Univariate analyses 
indicated no significant age- or education- differences between the clinical and control 
groups, t(21) = -.61, p < .55 for age, and t(21) = .56, p < .57, for education, which 
reflected the success of the matching process. As expected, none of the participants in 
the clinical or control groups were diagnosed with dementia at CSHA-1. However, 
significantly more participants in the clinical group were classified as having clinical 
impairment but no dementia (CIND) at CSHA-1 than were individuals in the control 
group (8 vs 0 respectively, χ2 (1, N =23) = 11.2, p < .01), suggesting that more 
individuals in the clinical group had subthreshold levels of cognitive impairment five 
years prior to clinical diagnosis.  
Measures. From the CSHA neuropsychological test battery, measures assessing 
global cognitive functioning (i.e., 3MS), episodic memory (i.e., BCRT), verbal fluency 
(i.e., FAS test and Animal Naming), and psychomotor speed (i.e., WAIS-R Digit Symbol 
Test) were chosen for analyses. To reiterate, these specific measures were selected for  
inclusion in the present study because they were administered in an unmodified manner 
in all three waves of the CSHA, and the cognitive domains assessed by the selected 
measures are typically reported to decline in dementia. In addition, the major goals of 
this study are identical to those of Study 1, involving English-speaking participants. 
Specifically, there was an interest in examining how French-speaking preclinical AD 
patients perform on the BCRT test, which has previously been suggested as an episodic 
memory test that is not influenced by other cognitive processes, such as impairments in 
attention and learning strategies. As well, there was a specific interest in examining the 
differential performance in phonemic vs category fluency measures in preclinical AD. 
Performance on a non-memory measure was assessed using the WAIS-R Digit Symbol 
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Table 7 
Demographic Summary For Clinical and Control French-speaking Participants 
  
Clinical Group 
 
Control Group 
 
Variable 
 
M 
 
SD 
 
M 
 
SD 
 
82.3 
 
5.8 
 
 
5.4 
 
3.1 
 
81.0 
 
6.5 
  
4.3 
 
2.7  
 
N 
 
N 
 
Age at CSHA-2 
 
Education 
 
 
 
 
Gender 
     Male 
     Female 
 
Residence at CSHA-2 
     Community 
     Institution 
 
CSHA-1 Diagnosis 
     NCI 
     CIND 
 
 
7 
5 
 
 
11 
1 
 
 
4 
8 
 
 
7 
4 
 
 
8 
3 
 
 
11 
 0 
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 subtest. Please refer to Table 2 in Study 1 for a summary of specific test scores 
analyzed in the present study.  
Statistical Analysis. Longitudinal changes in cognitive performance were 
examined for incident AD cases and healthy controls between initial assessment (CSHA-
1) and five year follow-up (CSHA-2). Separate 2(Group: Clinical vs. Control) X 2(Time: 
CSHA-1 vs. CSHA-2) repeated measures ANOVAs, with group as a between-subject 
variable and time as a within-subject repeated measure were conducted for each 
neuropsychological score. To further understand resultant interaction effects from these 
ANOVAs, post hoc analyses in the form of matched sample t-tests were conducted to 
examine mean-level differences between clinical and control groups at initial and 
reassessment. In addition, performance on the phonemic fluency and category fluency 
measures were directly compared with a 2(Group: Clinical vs Control) X 2(Task: FAS vs 
Animal Naming) X 2 (Time: CSHA-1 vs CSHA-2) repeated measures ANOVA, with 
group as a between-subject variable and task and time as within-subject repeated 
variables. The FAS and Animal naming scores were converted to z scores for analyses. 
ANOVA tables for the analyses of neuropsychological measures are presented in 
Appendix C. 
Results 
Global Indicator of Cognition. The 3MS performance of the French-speaking 
participants at CSHA-1 and CSHA-2 are presented in Table 8. There was a significant 
main effect of group explained by the poorer 3MS performance of the clinical group 
relative to the control group at CSHA-1 and CSHA-2, F(1,20) = 32.40, p < .001. There 
was also a significant main effect of time, F(1,20) = 6.95, p < .05 that was entirely 
explained by the participants in the clinical group who demonstrated a greater decline  
in 3MS performance between CSHA-1 and CSHA-2 assessments compared to their 
healthy counterparts. This group difference was confirmed by both the significant 
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Table 8 
3MS Performance for Clinical and Control Group Participants at CSHA-1 and  
 
CSHA-2 Assessments   
  
Clinical Group 
 
 
Control Group 
  
M 
 
SD 
 
M 
 
SD 
 
CSHA-1 
 
CSHA-2 
 
73.7 
 
60.5 
 
9.7 
 
10.2 
 
83.7 
 
85.0 
 
6.0 
 
8.3 
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interaction effect between group and time variables, F(1,20) = 10.32, p < .05 and by 
post-hoc analyses using matched sample t-tests which revealed a significant decline 
between CSHA-1 and CSHA-2 for the clinical group, t(11) = 3.46, p < .01 but not the 
normal control group, t(10) = -1.01, p = .33.  
Episodic Memory Measure (BCRT). Episodic memory performance (i.e., BCRT 
scores) of French-speaking clinical and control participants at initial assessment and 
follow-up is presented in Table 9. There were significant effects for diagnostic group and 
time on all four BCRT variables. As expected, participants in the clinical group performed 
more poorly with regard to retrieval, acquisition, retention, and delayed free recall of 
BCRT items at initial- and re-assessment compared to participants in the control group, 
F(1,19) = 28.43, p < .001 for retrieval, F(1,19) = 13.36, p < .01 for acquisition, F(1.21) = 
27.0, p < .01 for delayed free recall, F(1,21) = 13.79, p < .001 for retention. The 
significant main effect of time, F(1,19) = 26.62, p < .001 for retrieval, F(1,19) = 17.07, p < 
.01 for acquisition, F(1,21) = 19.2, p < .001 for delayed free recall, F(1,21) = 21.40, p < 
.001 for retention, reflecting a decline in performance between CSHA-1 and CSHA-2 
was qualified by significant Group X Time interactions for all variables, F(1,19)  
= 12.24, p < .01 for retrieval, F(1,19) = 18.00, p < .01 for acquisition, F(1,21) = 30.74, p < 
.01 for delayed free recall, F(1,21) = 21.40, p < .01 for retention. Post hoc analysis  
indicated that participants who progressed to develop AD between CSHA-1 and CSHA-2 
demonstrated a greater deterioration of performance over the five-year time period on all 
BCRT variables compared to healthy older adults (clinical group: t(9) = 4.53, p < .01 for 
retrieval, t(9) = 4.08, p < .01 for acquisition, t(11) = 4.09, p < .01 for delayed free recall, 
t(11) = 4.84, p < .01 for retention; control group: t(10) = 2.10, p  = .06 for retrieval, t(10) = 
-.27, p = .80 for acquisition, t(10) = 2.03, p = .07 for delayed free recall; note: t-statistic is 
not available for retention since control group participants did not exhibit any change in 
performance between CSHA-1 and CSHA-2. It is noteworthy that post hoc analysis for  
 54
Table 9 
Neuropsychological Test Performance of Clinical and Control Group Participants  
 
at CSHA-1 and CSHA-2 
  
Clinical Group 
 
Control Group 
 
Neuropsychological 
Measure 
 
 
M 
 
 
SD 
 
 
N 
 
 
M 
 
 
SD 
 
 
n 
 
BCRT 
 
  Retrieval  
     CSHA-1 
     CSHA-2 
 
  Acquisition 
     CSHA-1 
     CSHA-2 
 
Delayed Free Recall 
     CSHA-1 
     CSHA-2 
 
  Retention 
     CSHA-1 
     CSHA-2    
 
Fluency Measures 
 
  FAS 
     CSHA-1 
     CSHA-2 
 
  Animal Naming 
     CSHA-1 
     CSHA-2 
 
Digit Symbol 
     CSHA-1 
     CSHA-2   
 
 
 
 
22.2 
13.2 
 
 
34.8 
28.0 
 
 
8.1 
4.1 
 
 
11.6 
9.3 
 
 
 
 
13.8 
8.6 
 
 
9.9 
6.4 
 
 
14.2 
12.1 
 
 
 
 
4.6 
8.6 
 
 
1.9 
6.3 
 
 
2.1 
3.3 
 
 
0.8 
2.2 
 
 
 
 
5.4 
8.7 
 
 
2.1 
2.4 
 
 
7.5 
4.8 
 
 
 
 
10 
10 
 
 
10 
10 
 
 
12 
12 
 
 
12 
12 
 
 
 
 
10 
10 
 
 
12 
12 
 
 
9 
9 
 
 
 
 
28.1 
26.4 
 
 
35.6 
35.7 
 
 
10.3 
9.5 
 
 
12 
12 
 
 
 
 
17.1 
13.6 
 
 
13.6 
12.0 
 
 
23.9 
19.0 
 
 
 
 
2.0 
2.7 
 
 
0.9 
0.6 
 
 
1.2 
1.3 
 
 
0.0 
0.0 
 
 
 
 
6.8 
5.1 
 
 
3.9 
3.4 
 
 
7.1 
8.4 
 
 
 
 
11 
11 
 
 
11 
11 
 
 
11 
11 
 
 
11 
11 
 
 
 
 
9 
9 
 
 
11 
11 
 
 
11 
11 
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retrieval and delayed free recall performance of control participants all approached 
significance. This reflects a decline for the control group on these memory variables that 
is consistent with expected age effects. Limited power related to the small sample size 
likely hindered the possibility of finding statistical significance.  
Verbal Fluency Measures: FAS test and Animal Naming. Table 9 also shows the 
phonemic (FAS) and category (Animal Naming) fluency scores for French-speaking 
clinical and control groups at CSHA-1 and CSHA-2. Separate repeated measures 
ANOVA’s revealed a significant effect of time for the FAS variable, suggesting that 
participants in both the clinical and control groups demonstrated a decline in 
performance between the two assessment periods, F(1,17) = 6.05, p < .05. Main effect 
of group and interaction effect between time and group were not found to be significant 
for the FAS variable. With respect to the Animal Naming Test, significant effects of 
group, F(1,21) = 18.62, p < .001, and time, F(1,21) = 14.22, p < .01 were found; the 
interaction between these variables was nonsignificant. Evidently, clinical group 
participants recalled fewer animal names at initial assessment and at follow-up 
compared to control group participants and both groups of participants showed a decline 
in performance, recalling relatively fewer animal names at CSHA-2 and CSHA-1.  
Letter and category fluency scores were directly compared by converting each 
participant’s score on both measures to standard scores (z scores), expressed in 
standard deviations from the mean of an independent sample of healthy older adults 
(n=51; see Fig. 3). A 2 (Group: Clinical vs Control) X 2 (Task: FAS test vs Animal  
Naming) X 2 (Time: CSHA-1 vs CSHA-2) repeated measures AVOVA was performed 
with group as a between-subjects variable and task and time as within-subject repeated 
variables. A significant main effect of group was found, with the clinical group performing 
more poorly on both fluency measures at initial and reassessment relative to the control 
group, F(1,17) = 10.22, p < .01. As well, a significant main effect of time  
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Fig. 3. Standard scores of clinical and control group participants on FAS and 
Animal Naming tests administered in French. 
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suggested that the performance of clinical and control participants declined on both 
fluency measures between initial assessment and follow-up, F(1,17) = 15.17, p < .01. In 
addition, a significant interaction effect between task and group suggested that the 
difference in performance between the two groups is greater for the Animal Naming test 
than for FAS test at both CSHA-1 and CSHA-2, F(1,17) = 6.34, p < .05. No other main or 
interaction effects were observed.  
Psychomotor Speed Measure: WAIS-R Digit Symbol. Data for the Digit Symbol 
test (presented in Table 9) were analyzed using a 2 (Group: Clinical vs Control) X 2 
(Time: CSHA-1 vs CSHA-2) repeated measures ANOVA, with group as a between-
subject variable and time as a within-subject repeated variable. As with the English 
sample, significant main effects for group and time were found. Individuals diagnosed 
with AD at CSHA-2 performed significantly worse on the Digit Symbol test both at initial  
and reassessment relative to healthy older adults, F(1,18) = 7.71, p < .01. In addition, 
both groups of participants evidenced a significant decline in performance between the 
two assessment periods, F(1, 18) = 8.82, p < .01.  An interaction effect between the time 
and group variable was not significant.  
Discussion  
This study investigated the neuropsychological test performance of French-
speaking Canadians with incident AD, five years prior to clinical diagnosis. The present 
results indicate that French-speaking AD participants demonstrated lower performance 
on several of the neuropsychological measures at time of diagnosis and five years prior, 
compared to demographically-matched healthy seniors. However, compromised 
cognitive abilities were not uniform across all domains investigated. French-speaking 
individuals diagnosed with AD at CSHA-2 performed significantly lower than healthy 
controls on the global indicator (3MS), the episodic memory (BCRT), the category 
fluency (Animal Naming), and the psychomotor speed (WAIS-R Digit symbol) measures 
 58
at initial assessment (i.e., CSHA-1). In contrast, statistically significant group differences 
between clinical and control participants were not evident at CSHA-1 on the letter 
fluency (FAS test) task. In addition, French-speaking participants with AD demonstrated 
greater decline in performance between the CSHA-1 and CSHA-2 assessments on the 
3MS and the BCRT measures, but the decline in performance was comparable for both 
clinical and control groups on the verbal fluency (Animal Naming and FAS test), and 
psychomotor speed (WAIS-R Digit Symbol) measures.  
The results of the present study confirm the presence of preclinical changes in 
multiple cognitive domains in French-speaking Canadians, using traditional 
neuropsychological assessment measures. The finding that French-speaking AD 
participants demonstrate preclinical deficits in a global indicator of dementia (3MS) is 
consistent with other investigations that have used such instruments for assessing AD is 
diverse language groups. Decline in MMSE scores was reported for a Swedish sample 
three- to six-years before clinical diagnosis in a study by Small and his colleagues 
(2000). It is noteworthy that the MMSE and the 3MS were found to yield comparable 
reliability estimates when performance on these measures was directly compared in a 
study using a sample of English-speaking CSHA participants (Tombaugh, McDowell, 
Kritjansson, & Hubley, 1996).   
Even though English-speaking and French-speaking participants were not 
directly compared with statistical procedures in the present investigation, the similarities 
and differences in the performance trends between these groups are worthy of mention 
and discussion. First, preclinical deficits in the area of episodic memory were 
consistently noted for both language groups. Given that memory deficit is a principal 
diagnostic feature of AD, compromised episodic memory performance in the French-
speaking sample was confirmatory rather than surprising to find. However, the 
compromised performance of French-speaking AD participants on all free and cued 
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recall trials of the BCRT five years prior to diagnosis suggests that language may not 
mediate the ability of patients to benefit from supported encoding and retrieval. The 
overall finding of preclinical episodic memory deficit in a group of French-speaking 
seniors is consistent with other investigations that have sampled non-English speaking 
individuals (Bäckman et al., 2001; Marcoupulous, McLain, & Giuliano, 1997) and 
confirms that episodic memory deficit is a instrumental marker of preclinical AD.     
With regard to specific BCRT scores, it was discussed in Study 1 that Tuokko 
and her colleagues (1991) found that individuals with mild AD and healthy counterparts 
demonstrated comparable performance on the delayed recall trial of the BCRT. The 
present results do not support this finding. Similar to the English-speaking sample, 
French-speaking participants with incident AD at CSHA-2 demonstrated lower 
performance on the delayed recall trial of the BCRT compared to their healthy 
counterparts at time of diagnosis and five years prior. This finding is consistent with 
other investigations that have revealed that delayed memory measures are reliable in 
distinguishing individuals at risk of developing AD at a preclinical stage (Chen et al., 
2001; Linn et al., 1995; Saxton et al., 2004).    
Different trends in performance on the verbal fluency measures were evident for 
the English- and French- speaking samples. Compared to their healthy counterparts, 
English-speaking AD participants demonstrated weaker performance on both phonemic 
fluency (FAS) and category fluency (Animal Naming) tasks at initial assessment. In 
addition, they also demonstrated greater decline in performance between CSHA-1 and 
CSHA-2 on both measures. This was not the case with the French-speaking sample; the 
difference in performance between AD participants and normal controls was greater on 
the Animal naming test than the FAS test at both initial and reassessment.  
Several factors may have contributed to the above described discrepancies. 
First, it is noteworthy that performance on these language measures is known to be 
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significantly affected by educational attainment; individuals with more education tend to 
demonstrate better performance (Gasquoine, 1999; Kempler, Teng, Dick, Taussig, & 
Davis, 1998; Wiederholt et al., 1993). Thus, observed changes in performance between 
two assessment periods can be related to higher baseline ability for the more educated 
group. Collectively, the English-speaking participants in the current study had 
approximately 10 years of formal education (M = 9.98; SD = 4.3) compared to the 
French-speaking group that had approximately 6 years (M = 6.17; SD = 2.9) of formal 
education. In addition, comparison of raw scores indicates that English speaking 
participants indeed had higher baseline performance on both the FAS and Animal 
Naming measures compared to their French-speaking counterparts. It is suspected that 
the interaction between education and cognitive skills could have played a role in the 
observed discrepancies in performance on verbal fluency measures between the 
language groups. Second, issues of word fluency or salience may have contributed to 
the observed results. For example, the number of words beginning with “F”, “A”, and “S” 
may be different between the English and French languages and this may have resulted 
in fewer words being generated by the French-speaking sample.  
The present investigation was conducted to determine if differential performance 
on phonemic vs. category fluency (FAS > Animal Naming) measures is a consistent 
feature of preclinical AD. Investigators who have compared the performance of AD 
patients on phonemic and category fluency measures directly have found that patients 
are impaired relative to normal controls on the semantic, but not the phonemic fluency 
task (Butters et al., 1987; Monsch et al., 1994; Crossley, D’Arcy, & Rawson, 1997; 
Saxton et al., 2004). This differential performance was not observed with the English 
sample. However, in the French sample, AD patients demonstrated significantly poorer 
performance on Animal Naming compared to the FAS. At face value, this finding 
suggests that a semantic memory deficit, characterized by compromised performance 
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on a category fluency measure is a significant feature of preclinical AD in French-
speaking Canadians. However, as discussed above, word saliency and educational 
attainment may have served as confounding variables. In addition, linguistic factors may 
have also contributed to differences in Animal Naming ability. For example, Kempler et 
al. (1998) found significant ethnic differences in Animal Naming ability between 
members of five ethnic groups (African American, White, Chinese, Hispanic, and 
Vietnamese), assessed in their native language; Vietnamese-speakers produced the 
highest number and Spanish-speaking participants produced the lowest numbers of 
animal names in their sample. The authors attributed the exaggerated difference 
between these two groups to linguistic factors, namely that Vietnamese animal names 
on average are shorter and mono-syllabic while Spanish animal names are longer, 
involving 2 to 3 syllables per word than in the other languages involved in the study. It is 
not known if similar linguistic differences are apparent between the English and French 
languages. If so, such factors would serve as confounding variables in assessing 
performance between French- and English-speaking participants on the Animal Naming 
measures.     
Comparable trends in performance were evident between French- and English-
speaking participants on the WAIS-R Digit Symbol measure. Mainly, in both samples, 
compromised performance at a preclinical stage was evident for AD patients, but both 
clinical and control participants demonstrated a decline in performance between initial 
and reassessment. This supports previous investigations that have suggested that a 
decrease in speed of processing is a general mechanism evident in cognitive aging and 
is generally culturally invariant (Park, Nisbett, & Hedden, 1999). 
The advantages and limitations of the current study are similar to those of Study 
1. First, the use of a community-based sample allows for generalizability of results to 
other North Americans of French background. This study also accounts for changes in 
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normal aging by including healthy normal controls, and investigated change over a five 
year time period allowing for assessment of the cognitive decline of preclinical AD over 
time in a French-speaking sample. However, the small sample size was a notable 
limitation that likely led to limited power to accurately detect “true” cultural differences. 
For example, with regard to episodic memory performance, low power limited the ability 
to detect age-related cognitive decline in healthy controls, in turn artificially inflating 
performance differences between the cultural groups.    
The findings of the present study support the growing body of literature 
suggesting that language differences may play a role in cognitive performance 
(Gasquoine, 1999; Kempler et al., 1998; Manly, Jacobs, & Mayeux, 1999). Different 
cognitive performance trends were observed between English- and French-speaking 
Canadians particularly with regard to language-based verbal fluency measures. These 
differences should be taken into consideration if diagnostic decisions are made based on 
such instruments. The results of this study further highlight the importance and the need 
to study neuropsychological performance in diverse populations.  
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Studies 3 and 4: A Brief Introduction  
 Available treatments for AD appear to be most effective when prescribed at early 
stages of the disease (Kelly, Harvey, & Cayton, 1997). Consequently, a major goal in the 
clinical diagnosis of AD is the detection of the condition at the earliest possible stages. 
Previous investigations have found that AD patients exhibit subtle, isolated impairments 
in various cognitive domains long before the clinical signs of the condition become 
apparent (Arnáiz & Almkvist, 2003; Bondi & Monsch, 1998; Small, Mobly, Jonsson 
Laukka, Jones, & Bäckman; Tierney, Yao, Kiss, & McDowell, 2005). Consistent with 
these findings, the results of the first two studies in the present series of investigations 
also indicate that cognitive deficits can be detected at the preclinical stage of AD in 
samples of English- and French-speaking Canadians. Although some differences in 
cognitive performance were evident, in general, both English- and French-speaking 
participants from the CSHA were found to demonstrate compromised performance five 
years before clinical diagnosis on a global indicator of dementia, as well as on measures 
of episodic memory, verbal fluency, and psychomotor speed.  
The next two investigations were undertaken to examine the predictive value of 
the selected neuropsychological measures that were examined in Studies 1 and 2. 
Specifically, the goal was to determine how well the four core neuropsychological 
measures (i.e., BCRT, FAS test, Animal Naming, and WAIS-R Digit Symbol) distinguish 
individuals who progressed to develop AD from those who remained healthy over the 
five year time period between CSHA-2 and CSHA-3. In addition, there was also an 
interest in determining to what extent demographic variables such as age, gender, and 
education contribute to the prediction of dementia.  
Given that a significant limitation of Studies 1 and 2 was the small sample size, 
different participant selection and statistical analysis procedures were employed to 
determine the utility of the neuropsychological measures in predicting dementia. Study 3, 
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which is presented in manuscript format, involved English-speaking participants. This 
study also included an validation component. That is, the best predictors were used to 
determine who amongst an independent group of individuals, deemed to be at risk of 
developing AD, actually go on to meet criteria for dementia. The final study (i.e., Study 4) 
in this series was conducted to determine which neuropsychological and demographic 
predictors best distinguish French-speaking AD participants from those who remain 
healthy over a five year period.  
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Abstract 
Objective: To determine the utility of neuropsychological measures and demographic 
variables included in the Canadian Study of Health and Aging (CSHA) in predicting 
dementia over a five-year period.   
Background: Alzheimer disease (AD) patients exhibit deficits across multiple cognitive 
domains years before clinical diagnosis. Studies have not verified the efficacy of an 
established set of predictors to prognosticate outcome in an at-risk sample.      
Methods: The CSHA, a population-based study of dementia, was conducted in three 
waves (CSHA-1, 1990-1991; CSHA-2, 1996-1997; CSHA-3, 2000-2001). Different 
cohorts of English-speaking community residents who completed neuropsychological 
testing were included in prediction and validation analyses. First, CSHA-2 incident AD 
cases (n=78) and normal controls (n=147) were followed retrospectively to CSHA-1 to 
identify the neuropsychological and demographic variables that best discriminate these 
two groups. To determine the predictive validity of the significant variables, the variables 
were used to classify an independent group of CSHA-2 participants deemed to be at risk 
for AD and for whom diagnostic outcome was recorded at CSHA-3 (n=96).  
Results: Age, delayed free recall, and speeded visuomotor processing emerged as three 
significant predictors from logistic regression in the prediction analyses. The model was 
significant at χ2 (3) = 198.2, p<.001 (sensitivity: 88.5%; specificity: 93.9%). The three-
variable model was able to accurately classify 68% of individuals from an at risk sample. 
The overall classification analysis was significant at χ2 [1] = 12.1 p <.001 (sensitivity: 
69%; specificity: 67%). 
Conclusions: Age as well as performance on tests of memory and speeded visuomotor 
processing can identify individuals with high and low probabilities of developing 
dementia over a five-year time frame. 
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Introduction 
 Alzheimer Disease (AD) is characterized by subtle neuropsychological deficits 
that precede diagnostically significant cognitive, behavioural, and social changes (Bondi 
& Monsch, 1998; Small et al., 2003). The term “preclinical phase” is often used to 
describe the period between disease onset and subsequent clinical diagnosis. In recent 
years, there have been increasing developments in attempts to understand the precise 
characteristics of individuals in the preclinical phase of AD. Collectively, the studies in 
this area aim to accurately identify individuals at risk of developing dementia at the 
earliest possible stage in order to initiate effective treatments.  
Previous investigations have revealed numerous neuropsychological predictors of 
progression to AD (Arnáiz & Almkvist, 2003). Preclinical deficits have been shown in 
both global indicators of cognition, such as Mini-mental State Examination (Folstein, 
Folstein, & McHugh, 1975; Small et al., 2000) and in multiple specific domains of 
cognitive functioning, including attention (Linn et al., 1995; Perry & Hodges, 1999; 2000; 
Tierney et al., 1996), psychomotor speed (Masur et al., 1994), executive functions 
(Jacobs et al., 1995; Perry & Hodges, 1999; 2000), language ability (Flicker, Ferris, & 
Reisberg, 1991; Snowdon et al., 1996), and visuo-spatial skills (Mitrushina, Uchiyama, & 
Satz, 1995). However, memory deficits appear to be the most pronounced and 
consistent cognitive feature of preclinical AD. Numerous studies have shown that 
episodic memory deficits in preclinical AD exist for both verbal (Linn et al., 1995; Tierney 
et al., 1996) and non-verbal (Small et al., 1997) information, as well as for different 
retrieval conditions, including free recall (Linn et al., 1995; Grober, Lipton, Hall, & 
Crystal, 2000), cued recall (Bäckman & Small, 1998; Tuokko et al., 1991), and 
recognition (Bäckman, Small, & Fratiglioni, 2001; Fox at al, 1998). In addition, a recent 
investigation by Spaan and her colleagues (2005) revealed that semantic and implicit 
memory problems are also apparent in preclinical dementia and may explain some types 
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of episodic memory problems (i.e., compromised cued recall and recognition abilities) 
seen at this early stage.   
To identify preclinical neuropsychological predictors of AD, researchers have 
traditionally adopted research designs that involve either longitudinal or cross-sectional 
comparisons. The primary focus has been on determining the strength of the association 
between an indicator or predictor (i.e., neuropsychological measure or demographic 
characteristic) and dementia in terms of risk ratios and predictive power. To date, no 
studies have verified how well an established set of predictors can prognosticate who 
amongst a group of individuals deemed to be at risk for developing dementia will 
eventually progress to develop the disease. Validating an established set of predictors is 
imperative, as such information will aid in making meaningful and accurate prognostic 
judgments in clinical settings.  
The goals of the present study are twofold. First, we aim to determine the predictive 
value of select neuropsychological measures used in the Canadian Study of Health and 
Aging (CSHA). Specifically, we are interested in determining which of a select group of 
neuropsychological measures best distinguish individuals who developed AD from those 
who remained healthy over a five year time period. We are also interested in determining 
to what extent demographic variables, such as age, gender, and education contribute to 
the prediction of AD. These variables have previously been implicated as risk factors for 
AD. The chances of developing AD increase with age and low educational attainment 
(Launer et al., 1999; Lindsay et al., 2002). In addition, some investigations have found 
rates of AD to be higher among women than men (Launer et al., 1999). The second goal 
of the present study is to examine how well the best neuropsychological and 
demographic predictors, identified in the first set of analyses, can determine who 
amongst a second, independent group, of individuals deemed to be at risk of developing 
dementia, actually go on to meet diagnostic criteria for dementia. The two goals of this 
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study are addressed in separate sets of analyses, termed “prediction study” and 
“validation study” as described below.       
Background.  The Canadian Study of Health and Aging (CSHA) was a population-
based, longitudinal study that investigated the prevalence of dementia in Canadians 
aged 65 years and older. This CSHA was conducted in three waves; the first wave was 
carried out between 1990 and1991 (CSHA-1) and surviving participants were seen for 
follow-ups between 1996 and1997 (CSHA-2), and again between 2000 and 2001 
(CSHA-3). The longitudinal design of the study presents a unique opportunity to obtain 
both retrospective (e.g., CSHA-2 vs CSHA-1) and prospective (e.g., CSHA-2 vs CSHA-
3) information on the cognitive performance and diagnostic status of older Canadians. 
Different cohorts of participants (as described below) from the CSHA were identified for 
the prediction and validation phases of the present investigation. 
 A representative sample of individuals age 65 and over (n = 10,263) were drawn 
equally from five geographic Canadian regions (e.g., British Columbia, the Prairies, 
Ontario, Quebec, and the Atlantic region) and were included in the first wave of the 
CSHA. All participants were assessed in their preferred language of English or French. 
The CSHA drew samples from two distinct populations of individuals, residents of the 
community and residents of institutions. Only community-dwelling residents who were 
assessed in English were included for analysis in the prediction and validation phases of 
the present study. The Modified Mini-Mental State Examination (3MS; Teng & Chui, 
1987), a screening measure for cognitive impairment, was administered to the CSHA 
community-dwelling residents to determine who would be included in the clinical 
assessment component of the study. Individuals who obtained a 3MS score between 50 
and 78 out of a possible total score of 100 (i.e., potential cases), and a randomly 
selected subset of individuals who scored 78 or more out of 100 (i.e., potential healthy 
controls) were requested to undergo a clinical assessment.  
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 The clinical assessment component of the CSHA was designed to confirm the 
presence of dementia and to facilitate differential diagnoses. This component included a 
series of separate evaluations. First, a nurse collected medication information, re-
administered the 3MS, and interviewed a caregiver using a semi-structured version of 
the Cambridge Examination of Mental Disorders in Older Adults (CAMDEX; Roth et al., 
1988). Second, a trained psychometrician, blind to the information compiled by the 
nurse, administered the neuropsychological test battery to all participants who obtained 
a 3MS score between 50 and 78 on the nurse’s administration and to a random sample 
of those who scored over 78 (i.e., healthy controls). Subsequently, a neuropsychologist 
evaluated the neuropsychological test results and the CAMDEX data, based on the 
caregiver interview. Third, a physician performed a physical and neurological 
examination and made a preliminary diagnosis on the basis of this medical information 
and the nurse’s evaluation. Laboratory bloodwork was conducted for consenting 
participants suspected of having dementia. Finally, a consensus case conference was 
held during which the physician and the neuropsychologist reviewed their respective 
preliminary diagnoses, made a differential diagnosis, and arrived at a final consensus 
diagnosis based on all historical and currently available clinical information.  
 For CSHA-1 (data collected 1991-1992), diagnostic criteria for dementia were 
based on the Diagnostic and Statistical Manual of Mental Disorders, Revised Third 
Edition (DSM-III-R, American Psychiatric Association, 1987). Differential diagnosis for 
AD, depression, and other subcategories of dementias were based on the DSM-III-R, 
the criteria of the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA; McKhann et al., 1984), and the tenth revision of the International Classification 
of Disease (ICD-10; World Health Organization, 1992). Diagnostic categories included 
the following: no cognitive impairment (NCI), cognitive impairment but not dementia 
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(CIND), Alzheimer’s Disease (AD: probable or possible), Vascular Dementia (VD), other 
specific dementia, or unclassified dementia. It is noteworthy that the diagnoses of CIND 
was based on clinical impression and was given to individuals who neither met criteria 
for NCI or dementia (Tuokko et al., 2003)  
 Surviving participants from CSHA-1 were re-contacted for CSHA-2 five years 
later, between 1995 and1996, to examine the incidence, clinical progression, and 
mortality rates associated with dementia in Canada. The same research methodology 
described for CSHA-1 was used in CSHA-2 to determine participant eligibility for clinical 
and neuropsychological assessments. The third wave of the CSHA (i.e., CSHA-3) was 
conducted another five years later, between 2001 and 2002, with minor modifications in 
research design. CSHA-3 did not involve a nurse’s evaluation. Instead, during an initial 
screening interview a trained interviewer obtained information from a caregiver about the 
participant’s functional, cognitive, and medical status and administered the 3MS to the 
participant. The neuropsychological battery was abbreviated and administered to all 
remaining and consenting participants who did not have a diagnosis of dementia at 
CSHA-2 and who scored between 50 and 89 out of 100 on the 3MS at CSHA-3.  
The clinical assessments at CSHA-2 and CSHA-3 used the same diagnostic 
criteria as in CSHA-1. At CSHA-3, clinicians arrived at a consensus diagnosis in two 
stages. The first diagnostic decision was made without reference to the CSHA-2 
neuropsychological assessment results. Subsequently, all information, including 
assessment results from CSHA-1 and 2, was reviewed in preparation for a final 
consensus diagnostic decision.  
 Overall sample for current studies. As described earlier, only English-speaking, 
community-dwelling residents were included for analysis in the present studies. The 
decision to focus on this select sample was based on conclusions drawn from previous 
investigations that examined the neuropsychological assessment component of the 
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CSHA. Tuokko and her colleagues (1995) found significant differences in participation 
rates and diagnosis of dementia between English- and French- speaking participants. 
French-speaking participants living in the community demonstrated a higher refusal rate 
and were less likely than English-speaking participants to receive a dementia or a CIND 
diagnosis. Similarly, Steenhuis and Østbye (1995) found significant differences in 
neuropsychological performance between CSHA participants residing in the community 
and those living in institutions. Institutional residents presented with higher rates of 
cognitive dysfunction and subsequently were more likely to be diagnosed with dementia. 
Taken together, these investigations highlight the importance of considering language 
and sociodemographic factors when studying diverse populations of individuals.  Rather 
than attempt to control for these sociocultural factors using statistical methods, we 
decided to base the current study on the English-speaking community residing 
participants. Another factor that influenced the selection of our overall participant group 
was our interest in identifying individuals who are representative of those seen in clinical 
settings for diagnostic work-up. CSHA participants who were living in the community 
rather than in institutional care best represent those individuals typically referred to 
clinical settings for assessment  
In the present study, we began by examining the ability of CSHA 
neuropsychological measures and demographic variables to predict the development of 
AD over a 5-year period, between CSHA-1 and CSHA-2 in a sample of English-speaking 
Canadians residing in the community. Since memory impairment is a defining feature of 
AD, we hypothesized that measures of episodic memory will be sensitive at a preclinical 
stage to mild impairment in individuals who will progress subsequently to develop AD. 
Our second goal was to validate the neuropsychological and demographic predictors 
identified in the first phase of the study. Specifically, we were interested in determining 
how well these predictors can identify individuals who will progress to develop dementia 
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from a second sample of community dwelling Canadians from CSHA -2, presumed to be 
in the preclinical stages of dementia. The two goals of this study are addressed in 
separate sets of analyses, termed “prediction study” and “validation study” as described 
below. 
Prediction Study 
Methods 
Study Participants. A number of criteria were used to select participants for 
inclusion in this retrospective study, the main purpose of which was to determine which 
neuropsychological and demographic variables from CSHA-1 would best predict a new 
diagnosis of dementia at CSHA-2. The clinical group was comprised of participants who 
were first diagnosed with probable or possible AD at CSHA-2 (i.e., incident cases) and 
who underwent complete neuropsychological assessment at CSHA-1. This resulted in a 
group of 78 clinical participants; 30 participants in the clinical sample were classified as 
having NCI at CSHA-1 and the remaining 48 participants were diagnosed with CIND at 
CSHA-1. The control group was comprised of participants classified as cognitively 
normal (NCI) at CSHA-2 and with complete neuropsychological assessment data from 
CSHA-1. This yielded a sample of 147 control participants. It is noteworthy that no 
participants from the control group were classified as having dementia at CSHA-1. In 
addition, significantly more participants in the clinical group were classified as having 
CIND at CSHA-1 then were individuals in the control group (30 vs 16, respectively, χ2  (1, 
N = 225) = 64.24, p<.01) suggesting that more individuals in the clinical group had 
subthreshold levels of cognitive impairment five years prior to clinical. 
Measures. The CSHA neuropsychological examination included 12 measures 
designed to assess different domains of cognitive functions including memory, language 
ability, judgment, abstract thinking, and processing speed; these tests have been 
described in detail elsewhere (see Tuokko et al., 1995). From the test battery, candidate 
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neuropsychological measures assessing three domains of cognitive functioning (i.e., 
episodic memory, verbal fluency, and visuomotor speed) were chosen for inclusion in 
the present analyses because their utility as potential predictors of AD has been 
demonstrated in previous investigations (Crossley, D’Arcy, & Rawson, 1997; Masur et 
al., 1994; Tuokko et al., 1991). In addition, the chosen neuropsychological measures 
were administered in an unmodified fashion in all three waves of the CSHA and 
assessed areas of cognitive functioning typically reported to decline in dementia. 
Consequently, test scores from the Buschke Cued Recall Test (BCRT; Buschke, 1984; 
modified by Tuokko & Crockett, 1989) were included in the present analyses as 
measures of episodic memory, Animal Naming (Rosen, 1980) and the Controlled Oral 
Word Association Test (COWA, Spreen & Benton, 1977) were included as measures of 
verbal fluency, and the Digit Symbol subtest of the Wechsler Adult Intelligence Scale – 
Revised (WAIS-R; Wechsler, 1981) was included as a measure of speeded visuomotor 
processing. Gender, age, and education were also entered as predictors to investigate 
the predictive value of these demographic variables.  Please refer to Table 1 for a 
summary of the demographic and neuropsychological data from the clinical and control 
groups included in the Prediction Study.  
Prediction Study Statistical Methods. First, to examine how well the demographic 
variables and selected neuropsychological measures completed at CSHA-1 predicted 
incident AD at CSHA-2, direct logistic regression analysis was conducted. All variables 
were entered simultaneously (p to enter = .05). Next, another logistic regression was 
conducted with only those variables that significantly entered the forward logistic 
regression model to determine the predictive accuracy of these variables. Diagnostic 
category (i.e., AD vs NCI) was used as the outcome variable in all logistic regression 
analyses. The predictive accuracy of the final model was determined by examining the 
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Table 1 
Description of neuropsychological test scores included in the Prediction Study 
Measure/Scores Description 
Episodic Memory 
BCRT 
      
     Retrieval score 
     Acquisition score 
     Delayed free recall 
     Retention 
Verbal Fluency 
COWA 
 
     FAS Score 
 
Animal Naming 
 
     Animal naming score 
Psychomotor Speed of 
Processing 
WAIS-R Digit Symbol 
 
          Digit Symbol Score 
 
12-words, free and cued recall, selective reminding task 
with three-learning trials and a 20-min delayed trial 
free recall over three learning trials (max = 36) 
free and cued recall over three learning trials (max = 36) 
free recall at delayed trial (max = 12) 
free and cued recall at delayed trial (max =12) 
 
A phonemic fluency task that involves generation words 
beginning with the specific letters of the alphabet 
words generated in three 1-min trials each beginning with 
letters “F”, “A”, and “S”, respectively 
A semantic fluency task that involves generation of animal 
names in a 1-min trial 
animal names generated in a one-minute trial 
 
 
time-restricted symbol substitution task that involves 
pairing numbers and symbols according to a legend 
number of correctly paired number and symbols in 90-sec 
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sensitivity and specificity of the model, as well as the model’s positive and negative 
predictive values. All analyses were conducted using SPSS10 software.   
Results 
 The demographic characteristics and neuropsychological performance for the 
clinical and control groups at CSHA-1 are summarized in Table 2. There was a 
significant difference in gender distribution between the groups (χ2(1, N = 225) = 5.5, p < 
.05); the clinical group had a higher proportion of females than the control group (70 % 
vs 54%). In addition, participants in the clinical group were significantly older than those 
in the control group (M = 83.1 vs 75.9 yrs), t(1,223) = -9.6, p < .001, and had less formal 
education (M= 9.6 vs 11.4 yrs), t (1,223) = 3.6, p<.001.  
The direct regression analysis that incorporated the seven neuropsychological 
test scores and three demographic variables resulted in a statistically significant model, 
χ2 (10) = 204.6, p < .001. The results of this logistic regression are presented in the top 
section of Table 3. Of the candidate variables, age, the BCRT delayed recall score, and 
the WAIS-R Digit Symbol subtest score significantly contributed to the regression model.   
The results of the logistic regression involving only these significant variables are 
shown in bottom section of Table 3. A goodness-of-fit test revealed that the reduced 
three-variable model was also acceptable, χ2 (3) = 198.2, p < .001. The odds ratios 
indicate that age was the strongest indicator of progression to AD; with every one-year 
increase in age, participants are 1.2 times more likely to develop AD (age OR, 1.2; 95% 
CI, 1.1 - 1.3). In addition, the odds ratios for the neuropsychological measures indicate 
that for every unit increase in BCRT delayed recall score, the odds of developing AD are 
decreased by 49% (BCRT delayed recall OR, .51; 95% CI, .34 - .70), and for every unit 
increase in WAIS-R Digit Symbol score, the odds of developing AD are decreased by 
22% (WAIS-R Digit Symbol OR, .78; 95% CI, .71 - .86). One method of assessing the 
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Table 2 
Demographic Summary For Participants in the Prediction and the Validation Studies 
 Prediction Study Validation Study 
  
Clinical Group 
(incident AD) 
 
 
Control Group 
(NCI) 
 
CIND Group 
 
Number of Participants 
 
Gender 
 
     Females 
     Males 
 
Mean age at CSHA-1 
(SD) 
 
Mean Education 
(SD) 
 
78 
 
 
 
55 
23 
 
83.1 (5.1) 
 
 
9.6 (3.3)  
 
 
 
147 
 
 
 
80 
67 
 
75.9 (5.5) 
 
 
11.4 (3.8) 
 
96 
 
 
 
54 
42 
 
75.8 (6.4) 
 
 
10.3 (3.6) 
 
Neuropsychological 
Measure 
 
 
M* 
 
 
SD* 
 
 
M* 
 
 
SD* 
 
 
M** 
 
 
SD** 
 
  BCRT 
 
    Retrieval 
      
    Acquisition 
 
    Delayed Free Recall 
     
    Retention 
        
  Fluency Measures 
 
    FAS 
        
    Animal Naming 
        
  Digit Symbol 
        
 
 
 
18.2 
 
33.4 
 
6.7 
 
11.2 
 
 
 
21.4 
 
11.2 
 
18.7 
 
 
 
 
8.1 
 
4.9 
 
3.5 
 
1.7 
 
 
 
10.9 
 
3.3 
 
6.6 
 
 
 
 
27.9 
 
35.9 
 
10.4 
 
12.0 
 
 
 
32.9 
 
16.2 
 
35.8 
 
 
 
 
3.7 
 
.76 
 
1.4 
 
.2 
 
 
 
12.4 
 
4.3 
 
10.1 
 
 
 
20.1 
 
34.9 
 
7.3 
 
11.6 
 
 
 
22.4 
 
12.6 
 
23.7 
 
 
 
6.0 
 
2.3 
 
2.9 
 
.89 
 
 
 
10.7 
 
3.8 
 
9.4 
* CSHA-1 means and standard deviations; ** CSHA-2 means and standard deviations
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Table 3 
Results from Logistic Regression Predicting Alzheimer Disease in English-Speaking 
Canadians at CSHA-2 from Demographic and Neuropsychological Test Variables 
Variable Coefficient Wald P Value OR (95% CL) 
All Variables 
Sex 
 
Age at CSHA-1 
 
Education 
BCRT retrieve 
BCRT acquire 
BCRT delayed free recall 
BCRT retain 
Letter Fluency (FAS) 
 
Category Fluency (Animal) 
WAIS-R Digit Symbol 
 
Constant 
 
Significant Variables 
 
Age at CSHA-1 
BCRT delayed free recall 
WAIS-R Digit Symbol 
Constant 
 
-.32 
.20 
-.04 
-.08 
-.17 
-.58 
.71 
-.06 
-.01 
-.20 
-4.5 
 
.16 
-.67 
-.25 
-1.2 
 
.26 
9.2 
.15 
.84 
.20 
5.0 
.34 
2.2 
.01 
13.8 
.16 
 
9.0 
17.4 
29.0 
.002 
 
.61 
.002 
.70 
.36 
.66 
.03 
.56 
.14 
.91 
.00 
.69 
 
.003 
<.001 
<.001 
.97 
 
.73(.22-2.5) 
1.2 (1.1-1.4) 
.96(.79-1.2) 
.92(.77-1.1) 
.84(.39-1.8) 
.56(.34-.93) 
2.0(.19-21.6) 
.94(.87-1.0) 
.99(.83-1.2) 
.82(.74-.91) 
 
 
1.2 (1.1-1.3) 
.51 (.38-.70) 
.78 (.70-.85) 
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 overall adequacy of logistic regression models is to examine the classification of cases 
for purposes of determining predictive properties such as sensitivity and specificity. The 
classification table that summarizes the fit between the actual and predicted group 
membership with the three significant variables included in the equation is presented in 
Table 4. Overall, 92% of the cases were correctly classified. The model was able to 
correctly identify 69 of 78 participants who developed AD over a five-year period, 
yielding a sensitivity of 88.5%. In addition, 138 of 147 individuals who remained without 
dementia over five years were accurately classified, yielding a specificity of 93.9%. 
Overall, the model yields a positive predictive value of 88.5% in the ability to predict AD 
and a negative predictive value of 93.9% for the prediction of absence of AD. 
Discussion 
Our retrospective prediction study tested the ability of selected demographic 
variables and CSHA neuropsychological test scores to distinguish between seniors who 
will remain healthy and those who will develop AD during a subsequent five-year period. 
The results indicate that age, BCRT delayed recall score, and WAIS-R Digit Symbol 
score may be among the most sensitive early predictors of AD. A regression model 
comprised of these three predictor variables was able to accurately classify 92% of 
participants involved in the present investigation. The model was able to accurately 
predict progression to AD in 88.5% of individuals who actually developed the disease at 
CSHA-2. In addition, the model was also able to identify 93.9% of participants who 
remained disease free between CSHA-1 and CSHA-2. In general, these findings support 
previous investigations suggesting that declines in episodic memory and speeded  
visuomotor processing may be some of the earliest cognitive indicators of AD. If these 
findings can be generalized, knowledge of an individual’s age and scores on select 
neuropsychological measures can be used to identify seniors residing in the community 
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Table 4 
Classification Table for Prediction Study 
 Predicted Outcomes  
 Clinical Non-clinical Total 
Observed Outcomes 
     Clinical 
     Non-clinical 
 
69 
9 
 
9 
138 
 
78 
147 
Total 78 147 225 
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 who may be at either a very low or a very high risk of developing AD over a five-year 
period.  
The three-variable model identified in this study provides a method of using 
demographic and cognitive test information to predict probability of future diagnosis. An 
example of how chronological age as well as BCRT delayed recall and WAIS-R Digit 
Symbol scores can be used to calculate the probability that an individual will develop AD 
(or conversely, will not develop AD) within 5 years is described below. The probability of 
developing AD can be calculated using the following equation:  
Probability (AD) = 1/(1+ e-Z) 
where Z = Constant + β(significant variable) + β(significant variable) … 
The regression coefficients (i.e., β values) for the model can be found in Table 3. Thus, 
Z = -1.2 + .16 (age) - .67 (BCRT delayed free recall score) - .25 (WAIS-R digit symbol 
score) for our model.  
The probability of developing AD for an 86 year-old female client whose raw 
scores on the BCRT delayed free recall trial and on the WAIS-R Digit Symbol subtest 
were 10 and 31, respectively, will be calculated as follows: 
Z = -1.2 + .16 (86) - .67 (10) - .25 (31) = -1.89 and Probability (AD) = 1/(1+ e-(-1.89)) = 0.13 
These operations estimate that this client has a 13% probability of progressing to 
develop AD in 5 years. Conversely, using the same equation, it can be shown that the 
probability that a 86 year-old male client who received a score 8 on the BCRT delayed 
free recall trial and 23 on the WAIS-R digit symbol subtest will progress to develop AD 
over 5 years is considerably higher at 81%.   
Validation Study 
The CSHA provided a unique opportunity to conduct an actuarial validation study 
to examine how well our model could be generalized to predict diagnostic outcome for 
an independent sample of individuals at the preclinical stage of AD. In each wave of the 
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CSHA, the term “cognitive impairment but not dementia” (CIND) was adopted to refer to 
those participants whose cognitive difficulties did not reach the criteria for dementia. 
Individuals diagnosed with CIND were found to be 5 times more likely than individuals 
classified as having “no cognitive impairment” (NCI) to develop AD or dementia over a 
five year period (Tuokko et al., 2003). Conceptually, this suggests that a majority of 
individuals in the CIND category at any given wave of the CSHA are likely in the 
preclinical phase of dementia.  
Several subcategories of CIND2 were specified to account for the possibility that 
a variety of factors, including life-long impairments, fatigue, depression, sensory 
impairment, or physical disability could lead to identifiable cognitive declines in many 
areas. In the Validation Study, we examined how well the logistic regression model, 
based on the three significant predictor variables (i.e., age, BCRT delayed recall score, 
and WAIS-R digit symbol score), differentiated between a group of English-speaking 
participants who were diagnosed with CIND at CSHA-2 and who progressed to develop 
dementia five years later at CSHA-3 from those who remained without the clinical 
diagnosis.  
Methods 
Study participants. A number of criteria were used to select participants for inclusion 
in the validation section of the present study. The population of interest was English-
speaking, community-dwelling Canadians who were diagnosed with CIND at CSHA-2 for 
whom complete neuropsychological data were available at this wave and a final 
diagnosis was available at five-year follow-up (CSHA-3). Participants diagnosed with 
multiple sclerosis or epilepsy, and those who were blind or deaf were excluded from this 
                                                 
2 Subcategories of CIND identified in the CSHA included the following: delirium, alcohol abuse, 
drug abuse, depression, psychiatric history, age associated memory impairment, mental 
retardation, cerebral vascular disease, general vascular disease, Parkinson’s disease, brain 
tumour, Multiple Sclerosis, epilepsy, socio-cultural issues, social isolation, blind/deaf, and other 
reasons specified by diagnosticians.  
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study because these neurological and sensory problems were assumed to confound the 
diagnosis of dementia. These criteria for participant selection resulted in a study sample 
of 96 participants. Only participants with a CSHA-2 diagnosis of CIND were selected for 
inclusion in the study because these participants were deemed to be at risk of 
developing dementia and for purposes of results generalization, were conceptually 
considered to best represent the types of individuals who may be seen by clinicians for 
dementia assessment in the community. The demographic characteristics of this sample 
are summarized in Table 2. As shown in Table 2, participants in this sample, with a 
mean age of 75.8 years at CSHA-1 and mean education level of 10.3 years, were 
comparable, demographically, to normal controls in the prediction study. 
Measures and Validation Study Statistical Methods. Based on our logistic regression 
model for the reduced three significant variables (see Table 3), the predicted probability 
of developing or not developing dementia was calculated for each participant diagnosed 
with CIND according to the following formula:  
   Probability (AD) = 1/(1+ e-Z)  
where  Z = -1.2 + .16 (age) - .67 (BCRT delayed free recall score) - .25 (WAIS-R Digit 
Symbol score). All participants with a dementia probability of 50% or greater were 
assigned to the clinical group. Those with predicted probability of less than 50% were 
assigned to the nonclinical group. Accuracy of classification based on our model was 
compared to actual CSHA-3 diagnostic outcome for the participants. Chi-Square tests 
were conducted to analyze group classification. Likelihood ratios (LRs) were calculated 
to determine the usefulness of our model for diagnostic decision-making. All analyses 
were conducted using SPSS-10 statistical software (SPSS Inc. Chicago, ILL). 
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Results 
Of the 96 CSHA-2 participants diagnosed with CIND, 10 (10.4%) were assessed 
to be “normal” at CSHA-3, 44 (45.8%) individuals remained with CIND, and 42 (43.8%) 
were diagnosed with dementia. Of the 42 individuals who progressed to develop 
dementia at CSHA-3, 18 (42.9%) were diagnosed with probable AD and 8 (19%) with 
possible AD. The remaining 16 (38%) individuals were diagnosed with other forms of 
dementia (i.e., vascular, or other forms). 
The results of the classification analysis are presented in Table 5. The overall 
classification was significant, χ2 [1] = 12.1 p <.001. Using the regression equation, 47 of 
96 sample participants were predicted to develop dementia at five-year follow-up (i.e., 
CSHA-3). In actuality, 42 individuals from the sample were diagnosed with dementia 
using the CSHA-3 protocol.  
To assess the overall adequacy of the model, predictive properties of the logistic 
regression were examined. With the significant predictor variables (i.e., age, BCRT 
delayed recall score, and WAIS-R Digit Symbol score) included in the equation, 67.7% 
of the cases were correctly classified. The model was able to correctly identify 29 of 42 
participants who developed dementia over a five-year period, yielding a sensitivity of 
69.0%. In addition, 36 of 54 individuals who remained without dementia were accurately 
classified, yielding a specificity of 66.7%. Overall, the model yields a positive predictive 
value of 61.7% in the ability to predict dementia and a negative predictive value of 73.5% 
for the prediction of absence of dementia in a sample with documented cognitive 
impairment.  
To examine how well our three-variable regression model classified the 
individuals in the CIND group who progressed to develop probable or possible AD 
(n=26), we conducted an additional classification analysis. The model was able to 
correctly identify 19 of the 26 (73%) individuals who progressed to develop AD 
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Table 5 
Classification Table for Validation Study 
 Predicted Outcomes  
 Clinical Non-clinical Total 
Observed Outcomes 
     Clinical 
     Non-clinical 
 
29 
18 
 
13 
36 
 
42 
54 
Total 47 49 96 
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 (χ2 [1] = 5.5 p=.01). In addition, the model was also able to accurately identify 9 of the 
10 individuals who were diagnosed with CIND at CSHA-2, but were classified as 
“normal” at CSHA-3 (χ2 [1] = 6.4 p=.01). 
In terms of clinical decision-making, the usefulness of a diagnostic measure is 
determined by the accuracy with which it helps a diagnostician rule-in or rule-out disease 
in a patient. Likelihood ratios (LRs) are statistical accuracy measures that indicate the 
extent to which a given diagnostic test result should shift (i.e., raise or lower) a clinician’s 
initial suspicion (i.e., pretest probability) for the presence of disease in a patient after the 
result of tests are obtained (i.e., posttest probability). Clinicians typically base pretest 
probabilities on the prevalence of the disease. The “positive likelihood ratio” (LR+) for 
dementia indicates how much the pretest probability of having dementia increases if the 
test is positive, while the “negative likelihood ratio” (LR-) indicates how much the pretest 
probability of dementia decreases if the test is negative. If a test does not appreciably 
raise or lower the pretest probability, it is not considered diagnostically useful.  
Likelihood ratios are defined in terms of sensitivity and specificity: LR+ = 
sensitivity/(1-specificity) and LR- =(1-sensitivity)/specificity. For our reduced three-
variable model, LR+ was 2.07 the LR- was 0.46, for the prediction of dementia. 
According to the guidelines provided by Jaeschke et al. (1994), these LR values would 
generate small, but potentially important changes to pretest probabilities regarding the 
development of dementia over a 5-year period. Assuming that the pretest probability of 
progression to AD is 50% (1:1 odds), the LR+ value of 2.07 indicates that following a 
positive test result the posttest probability of developing AD would increase to 67% 
(2.07/3.07). Conversely, the LR- value of 0.46 indicates that a negative test result would 
decrease the posttest probability to 31% (0.46/1.46).  
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Discussion 
 A little less than half (45.8%) of the individuals diagnosed with CIND who were 
included in this study progressed to develop dementia over a five-year period. This 
conversion rate is similar to those found in other investigations with follow-up intervals of 
4 to 5 years. For example, in their review of longitudinal studies involving individuals with 
objective evidence of cognitive impairment that was insufficient to meet criteria for 
dementia, Tuokko and Frerichs (2000) reported that 48% to 69% of at-risk individuals 
were found to develop dementia by 5 years.  
Overall, the reduced three-variable regression model, consisting of age, BCRT 
delayed recall score, and WAIS-R Digit Symbol was relatively better at identifying 
individuals who were diagnosed with probable or possible AD than those who were 
diagnosed with “dementia”, a category, which included AD, vascular dementia, and other 
dementia (61.7% vs. 73%). This is not surprising given that our original prediction model 
was based on a sample of individuals who were diagnosed with incident AD at CSHA-2.  
Although there are no consensus standards for judging sensitivity and specificity, we 
assume that accuracy rates between 62 and 73% should generally be considered low 
because more than a quarter of the participants were misclassified. However, it is 
noteworthy that our model yielded LR values that according to evidence-based practice 
would provide a small but possibly important change in pretest to postest AD 
probabilities.  
General Discussion 
 This main purpose of the present study was to examine the efficacy of an 
established set of demographic and neuropsychological predictors in identifying 
individuals at risk of developing AD. We present the results of the first actuarial 
validation study and add to a growing body of literature that aims to characterize the 
preclinical stage of AD. Using logistic regression procedures, we found advanced age, 
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declines in episodic memory (measured by BCRT delayed recall score) and speeded 
visuomotor processing skills (measured by WAIS-R Digit Symbol subtest score) to be 
the most significant preclinical indicators of progression to AD. In addition, we began the 
validation process for this particular composite of predictive indicators. The results 
provide some evidence that a composite equation comprised of age, BCRT delayed 
recall score, and WAIS-R Digit Symbol score can be used to prognosticate who amongst 
a group of English-speaking Canadians deemed to be in the preclinical stages of 
dementia will eventually go on to develop the disease and who will remain without 
dementia. 
 Age emerged as the most significant predictor in our model. This is consistent 
with other investigations that have also suggested that advanced age is a significant 
demographic predictor of dementia (Small et al., 2000, Tierney et al., 2005). This is not a 
surprising finding given that the prevalence of dementia is known to increase 
exponentially with advanced age. Desai and Grossberg (2005) report that 4.5 million 
United States residents were living with AD in 2000; the prevalence of disease ranged 
from 5% in people aged 65 to 74 to almost 50% in those 85 years or older. Similarly, in 
Canada, 252 600 individuals 65 years of age and over were diagnosed with some form 
of dementia in 1991, with nearly 64% suffering from AD. The prevalence of dementia 
ranged from 2.4% among seniors aged 65 to 74, to 34.5% among those 85 years or 
older (Canadian Study of Health and Aging Working Group, 1994).   
Interestingly, however, gender did not emerge as a significant predictor of AD in 
our study. Notably, the distribution of men and women was significantly different in our 
prediction study samples, with more than twice the number of individuals in our clinical 
(i.e., incident AD sample) group being woman. Previous investigations have indicated 
that AD affects a greater proportion of women (Hill et al., 1996). The fact that gender did 
not emerge as a significant predictor in our study may be a reflection of the fact that 
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women tend to have a longer life span than men and are more prone to live with 
dementia into older age; the inclusion of age as a demographic predictor may have 
diminished the effect of gender in our sample. Given that we used a direct/simultaneous, 
and not a hierarchical, logistic regression procedure in this study, the possibility that the 
age variable diminished the effect of gender was not statistically analyzed.  
Using the CSHA dataset, Tierney and her colleagues (2005) found education to 
be an important predictor of AD 10 years before diagnosis. In their study, education did 
not emerge as a significant predictor at five years before diagnosis. Consistent with 
these results, education did not add significantly to our prediction model, which was 
based on a five-year time frame between initial assessment and AD diagnosis. Based on 
these findings, it is possible that effects of education on the prediction of AD may be 
related to the length of time between the initial and follow-up assessment periods. 
The neuropsychological measures that were significant predictors in our 
regression model (i.e., BCRT and WAIS-R Digit Symbol subtest) represent distinct 
cognitive areas that are known to decline in dementia. The BCRT is an episodic memory 
measure that has been found to be sensitive in the early detection of AD. The presence 
of early changes in episodic memory in our sample is generally consistent with the 
findings of several previous longitudinal and cross-sectional studies of dementia. 
Specifically, several other studies have also suggested that declines in delayed recall on 
a list-learning task, are among the most reliable measures for distinguishing between AD 
cases and normal controls (Bäckman et al., 2001; Chen et al., 2000; Masur et al., 1994; 
Tierney et al., 2005). In addition, using the BCRT in a prospective investigation, Tuokko 
and her colleagues (1991) found that participants who developed AD in the course of 12 
to 18 months evidenced poorer performance on free, cued, and delayed recall at initial 
assessment when compared to participants whose diagnostic status remained 
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unchanged over the same time period. Our results suggest that the BCRT delayed recall 
score is a significant predictor even five years prior to diagnosis.  
The episodic memory deficit seen in preclinical AD appears to reflect the 
underlying neuropathology seen at the earliest stages of the disease. Histopathological 
and morphological studies have revealed that the earliest brain changes in AD occur in 
the hippocampus and surrounding neocortex, mesial temporal lobe structures that have 
been strongly implicated in episodic memory in neuroimaging studies (Foundas et al., 
1997; Jack et al., 1997; Mega et al., 2002). In addition, delayed recall appears 
consistently superior to retrieval procedures such as immediate recall, cued recall, and 
recognition suggesting that the ability to encode information into long term storage for 
subsequent free recall is a more useful clinical predictor than other retrieval procedures.  
In the current investigation, we also found that the Digit Symbol subtest is a 
significant predictor of AD, five years prior to diagnosis. The Digit Symbol task is a 
measure of psychomotor performance, including motor persistence, sustained attention, 
response speed and visuomotor coordination and is known to be sensitive to response 
slowing that is associated with normal aging (Lezak, 1995). Storandt and Hill (1991) as 
well as Masur and his colleagues (1994) found Digit Symbol to be among the first tests 
to be affected in patients with mild AD. Our results support these previous findings.  
 Language disturbances, characterized mainly by word-finding deficits, are 
consistently observed in dementia. A number of studies have demonstrated that AD 
patients are impaired on a range of language-based tests, including verbal fluency 
measures. Particularly, performance on category fluency has been found to differentiate 
AD patients from healthy older adults and other amnesic patients more successfully than 
performance on letter fluency tasks (Crossley, D’Arcy, & Rawson, 1997; Monsch et al., 
1994: Saxton et al., 2004). In addition, several investigators have reported that category 
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fluency is a significant neuropsychological predictor of progression to AD (Chen et al, 
2001; Masur et al., 1994, Tierney et al., 2005).  
In the current investigation, category fluency did not add significantly to the 
regression model. The inconsistency in results between our study and those of other 
investigators who have found performance on category fluency to be sensitive to early 
changes in AD may be related to several factors, including differences in diagnostic 
criteria, variations in length of time between initial and follow-up assessments, and 
different combinations of neuropsychological measures being included in the 
assessments. Different domains of cognitive functions have been reported to decline at 
different rates between the period of disease onset and eventual AD diagnosis. Verbal 
ability is persumed to decline later in the AD disease process for most affected 
individuals. Studies that have indicated verbal and category fluency as significant 
predictors of AD have had typical follow-up assessment periods between 2.5 to 3 years 
(Arnáiz & Almkvist, 2003). Comparatively, our study attempted to identify cognitive 
markers 5 years before diagnosis, a time at which language functions may not have 
been sufficiently affected to emerge as significant indicators of progression to AD.  
It is noteworthy that in a recent study using the CSHA dataset, Tierney and her 
colleagues (2005) found Animal Naming to be among the most significant indicator of 
progression to AD 5 years prior to diagnosis. The inconsistency in results between our 
study and that of Tierney et al. (2005) may be related to the fact that our studies involved 
the analyses of different combinations of neuropsychological measures administered in 
the CSHA. Consequently, the effects of the category fluency measure may have been 
diminished in our sample due to the other measures we chose to include in our 
analyses.  
Our prediction model was derived from a community-based cohort selected from 
a population-based study. This participant selection procedure not only minimized 
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selection bias typically associated with studying patients and controls in clinical research 
settings, but also allowed for better generalizability of results. In support of this, a unique 
and important aspect of our study was that we were able to validate our findings of 
significant demographic and neuropsychological predictors of AD using an independent 
sample of individuals known to be at risk of developing dementia and for whom final 
diagnosis was available five years later. Our reduced three variable model had a positive 
predictive value of almost 62% and a negative predictive value of 73% in predicting 
dementia in participants known to be at risk (i.e., participants diagnosed with CIND). In 
addition, the LRs suggest that our three-variable model would provide a small but 
potentially important change in diagnostic decision making between pretest and posttest. 
The model we propose is not intended to replace a complete neuropsychological 
assessment. However, our findings can potentially have implications for the diagnosis 
and care of community dwelling patients who typically are seen in an outpatient clinical 
setting for diagnostic purposes. Our findings provide a method of using demographic 
and neuropsychological information to predict future diagnostic outcome, a challenging 
task that many clinicians face. We have provided information on how to calculate 
predicted probabilities of dementia based on our three-variable (age, BCRT delayed 
recall score, and the WAIS-R Digit Symbol subtest score) regression model.  
As is common in many population-based studies, our findings are limited to 
populations similar to our sample: English-speaking seniors who are residing in the 
community. In addition, the participant sample consisted mainly of individuals between 
65 to 85 years of age with slightly less than high-school level education. Our results may 
not apply to individuals from significantly different sociodemographic and ethnic 
backgrounds. As well, our validations study, involved participants with a CSHA diagnosis 
of CIND. Given this, our model will be most useful for individuals who are assessed by 
clinicians to have subthreshold levels of cognitive impairment and who may be at risk of 
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developing dementia.  Replicating our findings using similar methodologies in other 
diverse samples is essential to extend the generalizability of results to a broader range 
of individuals. In addition, it should be noted that more than 25% of participants were 
misclassified in our validation study. Our results highlight the urgent need to conduct 
more actuarial validation studies on the efficacy of preclinical AD indicators in predicting 
outcome.   
Overall, the results of this study lend further support to the notion that individuals 
in the preclinical stage of AD exhibit unique characteristics. Our model demonstrates 
that performance on tests of memory and speeded visuomotor processing, together with 
age, can identify individuals with high and low probabilities of developing dementia over 
a five-year time frame. 
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Study 4: Preclinical Neuropsychological Predictors of Alzheimer Disease in a 
French-Speaking Canadian Cohort 
Objectives 
A major goal in the clinical diagnosis of Alzheimer Disease (AD) is the detection 
of the condition in the earliest possible stages. Previous investigations have revealed 
that individuals with Alzheimer Disease (AD) exhibit subtle neuropsychological deficits 
years before the clinical signs of the condition become apparent (Bondi & Monsch, 1998; 
Small et al., 2003); preclinical cognitive deficits have been noted in numerous domains 
including memory, attention, language abilities, and psychomotor speed. However, 
decline in memory abilities appear to be the most consistent early predictor of 
progression to AD (Arnáiz & Almkvist, 2003; Small et al., 2003).  
A significant disadvantage of studies that aim to identify preclinical 
neuropsychological markers of AD is that nearly all investigations have involved English-
speaking seniors of dominant cultural identities. There is now substantial evidence that 
language can affect cognitive functions and subsequent diagnostic decision (Manly, 
Jacobs, & Mayeux, 1999). Indeed, the results of the first two studies in the present 
series of investigations suggest that there are differences in cognitive performance 
between English- and French-speaking seniors who were involved in the CSHA, 
particularly on language-based neuropsychological measures. In light of such 
discrepancies, results from the study of English-speaking participants may not be 
directly generalized to seniors from other linguistic backgrounds particularly for the 
purposes of making diagnostic decisions. A major objective of this current study is to 
extend previous work to examine which of a select group of CSHA neuropsychological 
measures and demographic variables would best predict dementia in French-speaking 
Canadians over a five-year period. 
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Methods 
Study Participants. See Appendix A for a detailed description of the CSHA.  A 
cohort of community dwelling residents who were assessed in French during all three 
waves of the CSHA were included for analyses in the present study. Due to the relatively 
small number of Canadians who completed the neuropsychological assessment in 
French at all waves of the CSHA, a modified participant selection criteria (from Study 3) 
was used to select participants for inclusion in this study. Given that the primary purpose 
was to determine which neuropsychological and demographic variables would predict 
progression to AD, French-speaking participants who were diagnosed with probable or 
possible AD for the first time (incident cases) at CSHA-2 or at CSHA-3 who also 
underwent neuropsychological assessment five years prior to each of these two waves, 
and for whom no neuropsychological data were missing were included in the clinical 
group. This resulted in a clinical group of 40 participants. The control group comprised 
participants who were not diagnosed with dementia (i.e., classified as not clinically 
impaired) at CSHA-2 and at CSHA-3 and for whom complete neuropsychological 
assessment data were available five years prior at CSHA-1 and CSHA-2, respectively. 
This yielded a sample of 101 control participants.  
Measures. From the CSHA neuropsychological test battery, a group of candidate 
neuropsychological measures assessing three domains of cognitive functioning (i.e., 
episodic memory, verbal fluency, and psychomotor speed) were chosen for inclusion in 
the present analyses. The measures included the Buschke Cued Recall Test (BCRT; 
Buschke, 1984, modified by Tuokko & Crockett, 1989), Controlled Oral Word Association 
Test (COWA, Spreen & Benton, 1977), Animal Naming test (Rosen, 1980), and the 
WAIS-R Digit Symbol (Wechsler, 1981) subtest. These measures are identical to the 
ones included in the above mentioned investigation of CSHA English-speaking sample. 
To reiterate, the neuropsychological variables were chosen for inclusion in the present 
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analyses because their utility as potential predictors of AD has been demonstrated in 
previous investigations (Crossley, D’Arcy, & Rawson, 1997; Masur et al., 1994; Tuokko 
et al., 1991), they were administered in an unmodified manner in all three waves of the 
CSHA, and they assessed areas of cognitive functions typically reported to decline in 
dementia. Gender, age, and education were also entered as predictors to investigate the 
value of these demographic variables in determining clinical outcome for French-
speaking Canadians. Previous investigations have found that the risk of developing AD 
increases with age and low educational attainment (Launer et al., 1999; Lindsay et al., 
2002). In addition, studies have also found that women are more likely than men to 
develop AD (Laurner et al., 1999).  
Statistical Methods. Direct regression analysis was conducted to examine how 
well the demographic variables and selected neuropsychological measures completed 
by participants at CSHA-1 and CSHA-2 predicted incident AD five years later. All 
variables were entered simultaneously (p to enter = .05). Next, a second logistic 
regression was conducted with only those variables that significantly entered the forward 
logistic regression model to determine the predictive accuracy of these variables. 
Diagnostic category (i.e., AD vs no cognitive impairment or NCI) was used as the 
outcome variable in all logistic regression analyses. All analyses were conducted using 
SPSS 10 software.  
Results 
The demographic characteristics and neuropsychological performance (five 
years prior to diagnosis) for the clinical and control samples are summarized in Table 10. 
There were significant differences in age and education between the two groups (age: 
t(1, 139) = -3.1, p < .01; education: t (1, 139) = 2.6, p < .01). Compared to control group 
participants, those in the clinical group were significantly older (M = 76.6 vs 73.1 years) 
 108
Table 10 
Demographic Summary For French-Speaking Clinical and Control Groups 
  
Clinical Group 
 
 
Control Group 
 
Number of Participants 
 
Gender 
 
     Females 
     Males 
 
Mean age at CSHA-1 
(SD) 
 
Mean Education 
(SD) 
 
 
40 
 
 
 
26 
14 
 
76.6 (6.1) 
 
 
6.7 (3.3) 
 
 
 
101 
 
 
 
73 
28 
 
73.1 (5.8) 
 
 
8.6 (4.1) 
 
Neuropsychological 
Measure 
 
 
M 
 
 
SD 
 
 
M 
 
 
SD 
 
  BCRT 
 
    Retrieval 
      
    Acquisition 
 
    Delayed Free Recall 
     
    Retention 
        
  Fluency Measures 
 
    FAS 
        
    Animal Naming 
        
  Digit Symbol 
        
 
 
 
20.0 
 
33.1 
 
7.4 
 
10.9 
 
 
 
14.3 
 
10.1 
 
16.5 
 
 
 
 
5.8 
 
4.4 
 
2.8 
 
2.0 
 
 
 
8.3 
 
3.1 
 
8.3 
 
 
 
 
28.0 
 
35.6 
 
10.6 
 
11.9 
 
 
 
21.5 
 
14.0 
 
27.9 
 
 
 
4.3 
 
.91 
 
1.3 
 
.21 
 
 
 
9.1 
 
4.0 
 
11.5 
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and had less formal education (M = 6.7 vs 8.6 years). Gender distribution between 
groups was found to be non-significant.  
The forward regression analysis that included all seven neuropsychological test 
scores and three demographic variables resulted in a statistically significant model, χ2 
(10, N = 141) = 84.88, p < .001. The results of this logistic regression are presented in 
the top section of Table 11. Of the candidate variables, sex, age, and the BCRT delayed 
free recall score significantly contributed to the model. It is noteworthy that the 
contribution of WAIS-R Digit symbol to the overall model approached significance.  
The three significant variables of the full model were entered into a separate 
logistic regression; the results of this analysis are presented in the bottom section of 
Table 11. A goodness-of-fit test revealed that the reduced three-variable model was also 
acceptable, χ2 (3, N = 141) = 74.2, p < .001. However, sex did not emerge as a 
significant variable in this reduced mode. The odds ratios indicate that age was the 
strongest indicator of progression to AD in the French-speaking sample; with every year 
increase in age, participants are 1.2 times more likely to develop AD (age OR, 1.2, 95% 
CI, 1.1-1.3). Among the neuropsychological measures, only BCRT delayed free recall 
was found to be a significant predictor. The odds ratio for this measure indicates that for 
every unit increase in BCRT delayed recall score, the odds of developing AD are 
decreased by 60% (BCRT delayed recall OR, .40; 95% CI, .28-.58) for French-speaking 
Canadians. 
One method of assessing the overall adequacy of logistic regression models is to 
examine the classification of cases for purposes of determining predictive properties 
such as sensitivity and specificity. The classification table that summarizes the fit 
between the actual and predicted group membership with the initial three significant 
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Table 11 
Results from Logistic Regression Predicting Alzheimer Disease in French-Speaking 
Canadians from Demographic and Neuropsychological Test Variables 
Variable Coefficient Wald P Value OR (95% CL) 
All Variables 
Sex 
 
Age at preclinical assessment 
 
Education 
BCRT retrieve 
BCRT acquire 
BCRT delayed free recall 
BCRT retain 
Letter Fluency (FAS) 
 
Category Fluency (Animal) 
WAIS-R Digit Symbol 
 
Constant 
 
Significant Variables 
 
Sex 
Age at preclinical assessment 
BCRT delayed free recall 
Constant 
 
1.6 
.16 
-.07 
-.05 
.13 
-.67 
-1.2 
.04 
-.11 
-.09 
5.8 
 
.81 
.14 
-.91 
-4.0 
 
4.9 
7.6 
.39 
.12 
.17 
5.1 
1.1 
.55 
.93 
3.3 
.50 
 
2.2 
9.7 
24.6 
1.1 
 
.03* 
.01* 
.53 
.73 
.68 
.02* 
.29 
.46 
.34 
.07 
.48 
 
.14 
<.01* 
<.001* 
.30 
 
4.8(1.2-19.5) 
1.2 (1.0-1.3) 
.93(.75-1.2) 
.96(.74-1.2) 
1.1(.62-2.1) 
.52(.29-.92) 
.32(.04-2.6) 
1.0(.94-1.1) 
.89(.71-1.1) 
.91(.83-1.0) 
 
 
2.3 (.77-6.7) 
1.2 (1.1-1.3) 
.40 (.28-.58) 
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 variables included in the equation is presented in Table 12. Overall, 84.4% of the cases 
were correctly classified. The model was able to correctly identify 24 of the 40  
participants who developed AD over a five-year period, yielding a sensitivity of 60%. In 
addition, 95 of the 101 individuals who remained without AD over five years were 
accurately classified, yielding a specificity of 94.1%. Overall, the model had a positive 
predictive value of 80% in the ability to predict AD and a negative predictive value of 
85.6% for the prediction of absence of AD.  
Discussion 
 The present retrospective prediction study was concerned with determining 
which of a select group of CSHA neuropsychological and demographic variables best 
distinguish between French-speaking Canadians who develop AD over a five-year 
period from those who remain healthy during the same time period. The results indicate 
that advanced age and compromised delayed episodic memory (i.e., BCRT delayed 
recall score) may be among the most sensitive early predictors of AD for French-
speaking Canadians. It is noteworthy that sex emerged as a significant predictor in the 
initial logistic regression analysis that included all seven selected CSHA 
neuropsychological and three demographic variables. However, sex did not significantly 
contribute to the reduced regression model when it was considered along with the other 
two significant variables, namely age and BCRT delayed recall score.  
The reduced regression model comprised of age and BCRT delayed recall score 
was able to accurately classify 84.4% of French-speaking participants involved in the 
present investigation. 80% of the individuals whom the model predicted would progress 
to AD actually developed the disease over five years. In addition, 85.6% of the 
participants who were predicted by the model to remain disease free were healthy at 
reassessment.  
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Table 12 
Classification Table Prediction of AD in French-speaking participants 
 Predicted Outcomes  
 Clinical Non-clinical Total 
Observed Outcomes 
     Clinical 
     Non-clinical 
 
24 
6 
 
16 
95 
 
40 
101 
Total 30 111 141 
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Age emerged as the most significant predictor of AD in French-speaking Canadians. 
This is consistent both with previous investigations as well as the above presented study 
involving English-speaking CSHA participants (Small et al., 2000; Tierney et al., 2005). 
Advanced age is a well-known risk factor for AD, regardless of an individual’s cultural 
background. Given this, the fact that age emerged as a significant predictor of AD in 
French-speaking Canadians is confirmatory rather than surprising. Although there are 
different prevalence estimates for individuals of various cultural backgrounds (Manly, 
Jacobs, & Mayeux,1999), the incidence of dementia is known to increase exponentially 
with advanced age in any given cultural group (Canadian Study of Health and Aging 
Working Group, 1994; Desai & Goldberg, 2005).   
 As was the case with English-speaking Canadians, gender and education did not 
emerge as significant predictors of AD for French-speaking seniors. The present finding 
is inconsistent with previous investigations that have found females as well as 
individuals with low educational attainment to have higher risks of developing AD (Hill et 
al., 1996; Launer et al., 1999). However, it is noteworthy that the effects of gender and 
education on AD do not appear to be unequivocal. Indeed, other investigators have not 
found sex and education to be significant predictors of incident AD (Cobb et al., 1995; 
Yoshitake et al., 1995). In addition, using the CSHA database, Lindsay and her 
colleagues (2002) found advanced age and lower educational attainment to be 
significant risk factors for AD. In contrast, gender was not associated with higher AD risk. 
Methodological differences, including sample size, selection and diagnosis criteria, and 
duration of follow-up may account for the discrepancies between studies.  
 The present results also suggest that the BCRT is sensitive to the early detection 
of AD in a French-speaking sample. The delayed recall score of this measure emerged 
as a significant predictor of progression to AD. This is consistent with previous findings 
that have suggested that decline in delayed recall on list-learning measures, reliably 
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distinguish between AD cases and normal controls. Bäckman and his colleagues (2001) 
also found this to be the case in their population-based study that aimed to predict 
dementia in a cohort of Swedish (i.e., non-English) speaking seniors.  
 The episodic memory deficit in preclinical AD is consistent with the underlying 
neuropathlogical changes seen at the earliest stages of the disease. Investigations have 
revealed that the earliest changes in the brains of AD patients occur in the hippocampus, 
a temporal lobe structure that has been strongly implicated in episodic memory 
(Foundas et al., 1997; Mega et al., 2002). Delayed free recall appears to be superior to 
other retrieval procedures, such as immediate recall, cued recall, and recognition in 
predicting AD, regardless of native languages. This finding suggests that the ability to 
encode information into long term storage for subsequent free recall may be a more 
useful clinical predictor than other retrieval procedures.  
 As with the English-speaking sample, verbal fluency measures did not emerge as 
significant predictors in the present study. This result is inconsistent with previous 
investigations that have found performance on category fluency to be more sensitive 
than performance on phonemic fluency in distinguishing between preclinical AD patients 
and healthy older adults (Chen et al., 2001; Masur et al., 1994; Tierney et al., 2005).   
Methodological differences, including differences in diagnostic criteria, variations in 
length of time between initial and follow-up assessments, and different combinations of 
neuropsychological measures in test batteries may account for these discrepancies. In 
addition, different domains of cognitive functions have been reported to decline at 
different rates between the period of disease onset and eventual AD diagnosis. For 
example, verbal ability is known to decline later in the AD disease process. Studies that 
have indicated verbal and category fluency as significant predictors of AD have had  
typical follow-up assessment periods between 2.5 to 3 years (Arnáiz & Almkvist, 2003). 
Comparatively, the present study attempted to identify cognitive markers 5 years before 
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diagnosis; a time at which language functions may not have been sufficiently affected to 
emerge as significant indicators of progression to AD.  
 Furthermore, there may be several confounding factors in attempting to predict 
AD in non-English groups using language-based measures. For example, performance 
on verbal fluency may be influenced by aspects of the language of administration. As 
discussed in Study 2, word fluency or salience (e.g., the number of words beginning with 
“F”, “A”, and “S”) may be different between English and other languages and this may 
moderate performance, leading to discrepancies in total number of words generated 
between members of diverse language groups. Thus, even if verbal fluency measures 
emerge as significant predictors of progression to AD in English- and French-speaking 
seniors, the generalizability of such results to different language groups must be done 
with caution.  
The prediction model in the present study was derived from a community-based 
cohort selected from a population-based study. This participant selection procedure not 
only minimizes selection bias typically associated with studying patients and controls in 
clinical research settings, but also allows for better generalizability of results. In addition, 
the consistencies in findings between the present study involving French-speaking 
participants and the above-reported investigation using English-speaking CSHA 
participants suggest that advanced age and delayed episodic memory are significant risk 
factors for AD regardless of individual’s language of origin.    
The model proposed in this investigation is not intended to replace a complete 
neuropsychological assessment. However, the findings can potentially have implications 
for the diagnosis of AD and the care of community dwelling, French-speaking 
Canadians. The findings provide a method of using demographic and 
neuropsychological information to predict future diagnostic outcome in this population; a 
challenging task faced by many clinicians.   
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There are several limitations to the present study. The current findings are limited 
to French-speaking seniors who are residing in the community. In addition, the 
participant sample consisted mainly of individuals in their mid-70s with slightly less than 
high-school level education. These results may not apply to individuals from significantly 
different sociodemographic backgrounds. In addition, it will be important to verify the 
results of the present investigation with a cross-validation sample of French-speaking 
individuals to determine the true efficacy of preclinical AD markers in predicting 
outcome.  
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General Discussion 
 Collectively, the four studies that constitute this dissertation examine the 
preclinical neuropsychological characteristics of English- and French-speaking AD 
participants from the Canadian Study of Health and Aging (CSHA). First, separate 
investigations, each involving English- and French-speaking participants, were 
conducted to compare neuropsychological performance between AD participants and 
demographic-matched healthy seniors at the time of diagnosis and five years prior. 
Second, studies were completed to determine which of a select group of CSHA 
neuropsychological and demographic variables best distinguish between seniors who 
progressed to develop AD from those who remained healthy over a five year period. An 
actuarial validation study was also conducted with a cohort of English-speaking 
participants; the main aim was to determine how well the best predictors of AD in this 
language sample prognosticate clinical outcome in an independent group of participants 
deemed to be at risk of developing dementia.  
At the onset, it is important to highlight two significant methodological features of 
the present investigations. First, English- and French-speaking Canadians were studied 
separately. Second, only a select group of neuropsychological measures from the CSHA 
neuropsychological battery was included for analyses. The rational to study the cognitive 
performance of English- and French-speaking Canadians independently was 
multifaceted. In light of previous investigations that have found language differences to 
affect cognitive performance (Manly, Jacobs, & Mayeux, 1999), there was an interest in 
determining if language-related cognitive trends are evident in a Canadian population. In 
addition, there was an interest in considering the impact educational differences, 
between the English- and French- speaking CSHA participants, have on cognitive 
performance, without the use of statistical procedures. French-speaking participants 
were significantly less educated than their English-speaking counterparts in the CSHA. 
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However, statistical procedures that equate diverse groups on years of education before 
assessing cognitive performance do not necessarily guarantee that the quality of 
education received is comparable (Manly, Jacobs, & Mayeux, 1999).  Thus, the decision 
was made to study the two language groups independently. 
All four studies presented above involved a select group of neuropsychological 
measures (i.e., the BCRT, FAS test, Animal Naming, and WAIS-R Digit Symbol) that 
were chosen from the CSHA neuropsychological assessment battery. These measures 
were selected for several reasons. First, they were administered in an unmodified 
fashion in all three waves of the CSHA. Second, they represent cognitive domains that 
have been found to be affected in early AD (Arnaiz & Almkvist, 2003; Small et al., 2003; 
Tuokko et al., 1991). Third, there was a specific interest in investigating performance on 
the BCRT, a measure that controls encoding and retrieval, and thus, is deemed to be a 
better estimate of episodic memory than other list-learning tasks (Tuokko & Crockett, 
1989). Finally, there was an interest in investigating the diagnostic value of verbal 
fluency measures; previous investigations have found that individuals with AD 
demonstrate disproportionate declines in category fluency (e.g., Animal Naming) as 
opposed to phonemic fluency (e.g., FAS test; Butters et al., 1987; Crossley et al., 1997; 
Monsch et al., 1994). The present studies aimed to determine if this pattern was 
observable at the preclinical stage in the CSHA. It is noteworthy that the measures 
selection procedure used in this study did not allow for the evaluation of other cognitive 
domains, such as confrontational naming and visuo-spatial abilities that have been 
implicated to decline in AD (Arnáiz & Almkvist, 2003; Small et al., 2000). 
Overall, the present results indicate that both English- and French-speaking AD 
participants demonstrate cognitive changes in multiple domains at the preclinical stage. 
For the English-speaking sample, compromised performance was evident on a global 
indicator of cognition (i.e., 3MS), as well as on measures of episodic memory (i.e., 
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BCRT), phonemic fluency (i.e., FAS test), category fluency (i.e., Animal Naming), and 
speeded psychomotor skills (i.e., WAIS-R Digit Symbol) five years prior to diagnosis. In 
addition, English-speaking AD participants demonstrated significant decline in 
performance between initial and reassessment on all neuropsychological measures 
compared to their healthy counterparts. Advanced age, as well as declines in episodic 
memory (measured by BCRT delayed recall score) and psychomotor skills (measured 
by WAIS-R Digit Symbol score), were found to be the most significant indicators of 
progress to AD in the English-speaking sample.  
 Results for the French-speaking sample indicate that the AD participants 
performed significantly worse than healthy controls on a global indicator of dementia as 
well as on measures of episodic memory, category fluency, and psychomotor speed five 
years prior to diagnosis. However, unlike their English-speaking counterparts, significant 
differences in performance between clinical and control participants were not evident on 
the phonemic fluency task at initial assessment for French-speaking participants. In 
addition, French-speaking AD participants demonstrated greater decline in performance 
between CSHA-1 and CSHA-2 assessments on the 3MS and the BCRT measures. In 
contrast, decline in performance was comparable for both clinical and control groups on 
the Animal Naming, FAS, and WAIS-R Digit Symbol measures. In the French-speaking 
sample, advanced age and decline in delayed episodic memory (i.e., BCRT delayed 
recall score) were found to be the most significant indicators of progression to AD over a 
five year period. 
 Preclinical and longitudinal declines in episodic memory were consistent findings 
in the English- and French-speaking samples. Moreover, next to advanced age, which is 
noted to be a ubiquitous risk factor for dementia in various cultural and language groups 
(Lindsay et al., 2002; Manly, Jacobs, & Mayeux, 1999), compromised delayed episodic 
memory was the next best predictor of progression to dementia for both language 
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groups in the present investigations. The presence of early changes in episodic memory 
in the current studies is generally consistent with findings of several previous longitudinal 
and cross-sectional studies of dementia. Other investigators have found that declines 
during delayed recall trials on list-learning tasks are among the most reliable measures 
for distinguishing between AD cases and normal controls (Bäckman et al., 2001; Chen et 
al., 2001; Masur et al., 1994; Tierney et al., 2005).  
Given that memory deficit is a principal diagnostic feature of AD, the overall 
finding of preclinical changes in this area is not surprising. However, the use of the 
BCRT to assess episodic memory is a unique feature of the present study. As 
mentioned previously, the BCRT is considered a better memory measure compared to 
other list-learning tasks because performance on this task is less influenced by deficits in 
other cognitive domains (e.g., attention and executive functions). Using the BCRT in a 
prospective study, Tuokko and her colleagues (1991) found that participants who 
developed AD in the course of 12 to 18 months evidenced poorer performance on free 
and cued recall at initial assessment when compared to participants whose diagnostic 
status remained unchanged over the same time period. The present results indicate that 
compromised performance on the BCRT is present even five years prior to diagnosis 
regardless of language of administration. In addition, the findings that French-speaking 
AD participants also demonstrated compromised performance on all free and cued recall 
trials at a preclinical stage suggests that language may not mediate the ability of 
participants to benefit from supported encoding and retrieval procedures. 
It is noteworthy that an incidental observation in Tuokko et al.’s (1991) study was 
that performance on the delayed free recall trial of the BCRT was comparable between 
individuals with mild AD and their healthy counterparts. In contrast, in the present series 
of investigations, delayed free recall performance emerged as the most significant 
predictors of progression to AD in both the English- and French-speaking samples. The 
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difference in results between the two investigations may be related to methodological 
variations such as differences in sample selection, duration of follow-up assessments, 
and diagnostic procedures; the present series of investigations involved a larger 
community based sample with participants who were assessed at five-year intervals. In 
addition, the diagnosis of dementia was given following a multi-step assessment process 
that involved clinical and neuropsychological assessments as well as laboratory 
investigations and corroborative information from caregivers.  
The episodic memory deficit seen in preclinical AD reflects the underlying 
neuropathology seen at the earliest stages of the disease. Histopathological and 
neuroimaging studies have revealed that the earliest brain changes in AD occur in the 
hippocampus, a temporal lobe structure that has been strongly implicated in episodic 
memory (Foundas et al., 1997; Jack et al., 1997; Mega et al., 2002). In addition, given 
that the delayed recall appears to differentiate between participants subsequently 
diagnosed with AD and normal controls better than other recall procedures, such as 
immediate recall, cued recall, and recognition, suggests that the ability to encode 
information into long term storage for subsequent free recall may be a more useful 
clinical predictor than other retrieval procedures, regardless of language of test 
administration.     
The main differences in preclinical cognitive performance between the English- 
and French-speaking samples were found on language-based verbal fluency measures. 
As mentioned previously, a major goal of the present series of investigations was to 
determine if semantic memory deficits (assessed by performance on a category fluency 
task) is a reliable marker of preclinical AD. Previous investigations have found AD 
patients demonstrate poorer performance on category fluency tasks compared to 
phonemic fluency tasks at an early stage of the disease (Butters et al., 1987; Monsch et 
al., 1994; Crossley et al., 1997; Saxton et al., 2004). In addition, several investigators 
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have reported that category fluency is a significant neuropsychological predictor of 
progression to AD (Chen et al., 2001; Masur et al., 1994). The present studies found that 
for French-speaking participants, the difference in performance between the clinical and 
control groups was greater on the Animal Naming task than for the FAS measure at both 
time of diagnosis and five years prior. This pattern of performance was not observed 
with the English-speaking cohort, where participants demonstrated significant decline in 
performance on both fluency measures between initial and reassessment compared to 
their healthy counterparts. In addition, neither the category nor phonemic fluency 
measure emerged as a significant predictor of AD for either language group.  
Conceptually, it is not overly surprising that the most significant differences in 
cognitive trends between the English- and French-speaking samples occurred on 
language-based measures. Several factors including differences in educational level and 
word saliency could have contributed to the discrepancies in results between the two 
language groups. In addition, the inconsistency in results between the current 
investigations and those of other researchers who have found performance on category 
fluency to be sensitive to early changes in AD may be related to several factors, 
including differences in diagnostic criteria, variations in length of time between initial and 
follow-up assessments, and different combinations of neuropsychological measures 
being included in the assessments and regression models. Different domains of 
cognitive functions have been reported to decline at different rates between the period of 
disease onset and eventual AD diagnosis. Verbal ability has been found to decline later 
in the AD process. Studies that have indicated verbal fluency measures as significant 
predictors of AD have generally had longitudinal assessment follow-up periods between 
2.5 to 3 years (Arnaiz & Almkvist, 2003). Comparatively, the current studies attempted to 
identify cognitive markers 5 years prior to diagnosis; at a time when language and 
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consequently semantic memory functions may not have been sufficiently affected to 
emerge as significant indicators of progression to AD.  
It is noteworthy that in a recent study using the CSHA dataset, Tierney and her 
colleagues (2005) found Animal Naming to be among the most significant indicators of 
progression to AD 5 years prior to diagnosis. The inconsistency in results between the 
current investigations and that of Tierney et al. (2005) may be related to the fact that the 
present studies involved the analyses of different combinations of neuropsychological 
measures administered in the CSHA. Consequently, the effects of the category fluency 
measure may have been diminished in the present samples due to the other measures 
included in the analyses. 
Performance on the WAIS-R Digit Symbol task was investigated to assess 
functioning in a non-memory domain. As mentioned above, both English- and French- 
speaking participants demonstrated compromised performance at a preclinical stage, 
but this speeded psychomotor task emerged as a significant predictor of AD in the 
English-speaking sample. The former finding supports previous investigations showing 
that a decrease in speed of processing is a general mechanism evident in cognitive 
aging and is generally culturally invariant (Park, Nisbett, & Hedden, 1999). It is 
noteworthy that the WAIS-R Digit Symbol measure approached significance in the 
prediction of AD in the French-sample; the comparably smaller sample may have 
accounted for the discrepancy in results.  
The CSHA provided a unique opportunity to conduct an validation study to 
examine how well the emergent predictors of AD can be generalized to predict 
diagnostic outcome for an independent sample of individuals at the preclinical stage of 
AD. Results from the regression analysis of English-speaking participants was used to 
classify an independent group of participants who were diagnosed with CIND at CSHA-2 
and for whom diagnostic outcome was known five years later at CSHA-3. The reduced 
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three-variable model for English-speaking participants, consisting of age, BCRT delayed 
recall score, and WAIS-R Digit Symbol score had a positive predictive value of almost 
62% and a negative predictive value of 73% in predicting dementia in participants known 
to be at risk (i.e., participants diagnosed with CIND). In addition, the LRs suggest that 
the three-variable model would provide a small but potentially important change in 
diagnostic decision making between pretest and posttest. 
There are several advantages to the current series of investigations. First, the 
studies involved community-based cohorts selected from a larger population-based 
study. The participant selection procedure minimized the selection bias typically 
associated with studying patients and volunteers in clinical research settings and 
allowed for better generalization of results. Second, the longitudinal assessment of 
cognitive change over a five year time period allowed for assessment of cognitive 
decline over time, minimizing the potential confounds encountered in the study of one-
time cognitive performance. Third, the studies accounted for the cognitive changes of 
normal aging by including healthy English- and French-speaking seniors. Unique 
aspects of the present investigations were that English- and French-speaking 
participants were studied individually and attempts were made to validate findings of 
significant predictors of AD using an independent sample of English-speaking individuals 
known to be at risk of developing dementia.  
Ultimately, advanced age and delayed episodic memory emerged as significant 
predictors of AD in both the English- and French-speaking samples. The regression 
models proposed for each of these language groups are not intended to replace 
complete neuropsychological assessments. However, the present findings can have 
implications for the diagnosis AD and care of community dwelling older individuals of 
English and French backgrounds in Canada. Future diagnoses of illness is a challenging 
task faced by many clinicians; the present results provide clues about domains of 
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cognitive functions or what measures are significant in predicting outcome in both 
English- and French-speaking populations. Increased vigilance and referral for an 
extensive medical and neuropsychological assessment should be considered, if the 
proposed regression models from the present studies are used to predict risk of 
developing AD in clinical practice.  
As is common in many population-based studies, the present findings are limited 
to English- and French-speaking seniors who are residing in the community. In addition, 
participants from the two language groups were mainly individuals between the ages of 
65 to 85 with less than high-school level education. Moreover, it is noteworthy, that the 
French-speaking participants had significantly less formal education than their English-
speaking counterparts.  Overall, results may not apply to individuals from significantly 
different sociodemographic or ethnic backgrounds. In addition, dementia patients were 
not followed until death in the CSHA. As such, the diagnosis of dementia was solely 
based on clinical judgment and was not confirmed with autopsy procedures.    
The results of the present series of investigations lend further support to the 
notion that individuals in the preclinical stage of AD exhibit unique cognitive 
characteristics. Advanced age as well as performance on tests of episodic memory can 
identify English- and French-speaking individuals who develop AD with reasonable 
accuracy over a five-year period.  
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Appendix A 
A Description of the Canadian Study of Health and Aging 
The Canadian Study of Health and Aging (CSHA) was a population-based, 
longitudinal study that investigated the prevalence of dementia in Canadians aged 65 
years and older. This CSHA was conducted in three waves; the first wave was carried 
out between 1990 and1991 (CSHA-1) and surviving participants were seen for follow-
ups between 1996 and1997 (CSHA-2), and again between 2000 and 2001 (CSHA-3).   
A representative sample of individuals aged 65 and over (n = 10 263), were drawn 
equally from five geographic Canadian regions (e.g., British Columbia, the Prairies, 
Ontario, Quebec, and the Atlantic region) and included in the first wave of the CSHA. All 
participants were either residents of the community or residents of institutions, and were 
assessed in their preferred language of English or French.  
The Modified Mini-Mental State Examination (3MS; Teng & Chui, 1987), a screening 
measure for cognitive impairment, was administered to the CSHA community-dwelling 
residents to determine who would be included in the clinical assessment component of 
the study. Individuals who obtained a 3MS score between 50 and 78 out of a possible 
total score of 100 (i.e., potential cases), and a randomly selected subset of individuals 
who scored 78 or more out of 100 (i.e., potential healthy controls) were requested to 
undergo a clinical assessment.  
 The clinical assessment component of the CSHA was designed to confirm the 
presence of dementia and to facilitate differential diagnoses. This component included a 
series of separate evaluations. First, a nurse collected medication information, re-
administered the 3MS, and interviewed a caregiver using a semi-structured version of 
the Cambridge Examination of Mental Disorders in Older Adults (CAMDEX; Roth et al., 
1988). Second, a trained psychometrician, blind to the information compiled by the 
nurse, administered the neuropsychological test battery to all participants who obtained 
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a 3MS score between 50 and 78 on the nurse’s administration and to a random sample 
of those who scored over 78 (i.e., healthy controls). Subsequently, a neuropsychologist 
evaluated the neuropsychological test results and the CAMDEX data, based on the 
caregiver interview. Third, a physician performed a physical and neurological 
examination and made a preliminary diagnosis on the basis of this medical information 
and the nurse’s evaluation. Laboratory bloodwork was conducted for consenting 
participants suspected of having dementia or delirium. Finally, a consensus case 
conference was held during which the physician and the neuropsychologist reviewed 
their respective preliminary diagnoses, made a differential diagnosis, and arrived at a 
final consensus diagnosis based on all historical and currently available clinical 
information.  
 For CSHA-1 (data collected 1991-1992), participants were classified as 
cognitively normal (i.e., no cognitive impairment; NCI), cognitively impaired by not 
meeting criteria for dementia (i.e., cognitively impaired but no dementia; CIND) or 
demented (i.e., according to the Diagnostic and Statistical Manual of Mental Disorders, 
Revised Third Edition; DSM-III-R, American Psychiatric Association, 1987). It is 
noteworthy that the diagnoses of CIND was based on clinical impression and provided to 
individuals who neither met criteria for NCI or dementia (Tuokko et al., 1993). In addition, 
those with Alzheimer Disease (AD) were subclassifed according to the National Institute 
of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease 
and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984) criteria. A 
diagnosis of probable AD was given to individuals: with dementia established by clinical 
examination, documented by the Mini-mental State Examination, and other 
neuropsychological testing; deficits in two or more areas of cognition, progressive 
worsening of memory or other cognitive functions; no disturbance of consciousness, 
onset between the ages of 40 and 90, but most often after 65; and the absence of 
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systemic disorders or other brain diseases that independently could account for the 
progressive deficits in memory and cognition. A diagnosis of possible AD was given to 
individuals who met the criteria for probable AD, but also displayed/had one or more of 
the following: an atypical presentation/course (e.g., major aphasia, apraxia); a history of 
vascular problems (e.g., stroke or hypertension), Parkinsonism extrapyramidal signs, or 
had a coexisting disease. The tenth revision of the International Classification of Disease 
(ICD-10; World Health Organization, 1992) criteria were used to define vascular and 
other specific types of dementia. These criteria will not be discussed further as they are 
irrelevant to the present studies.  
 Surviving participants from CSHA-1 were re-contacted for CSHA-2 five years 
later, between 1995 and1996, to examine the incidence, clinical progression, and 
mortality rates associated with dementia in Canada. The same research methodology 
described for CSHA-1 was used in CSHA-2 to determine participant eligibility for clinical 
and neuropsychological assessments. Following the clinical assessment, two separate 
diagnosis were made. First, an incidence diagnosis was made using the same 
diagnostic criteria as in CSHA-1. Second, a new-criteria diagnosis was made using the 
DSM-IV (American Psychiatric Association, 1994) criteria for AD and new criteria for 
vascular dementia (Roman, Tatemichi, Erkinjuntti, et al., 1993) were applied.   
 The third wave of the CSHA (i.e., CSHA-3) was conducted another five years 
later, between 2001 and 2002, with minor modifications in research design. CSHA-3 did 
not involve a nurse’s evaluation. Instead, during an initial screening interview a trained 
interviewer obtained information from a caregiver about the participant’s functional, 
cognitive, and medical status and administered the 3MS to the participant. The 
neuropsychological battery was abbreviated and administered to all remaining and 
consenting participants who did not have a diagnosis of dementia at CSHA-2 and to 
those who scored between 50 and 89 out of 100 on the 3MS at CSHA-3.  
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At CSHA-3, an initial or incidence consensus diagnosis was made using the 
diagnostic criteria used in CSHA-1. As in CSHA-2, a new criteria diagnosis was made 
using DSM-IV and NINCDS-ADRDA criteria for AD. In addition, CIND was diagnosed 
using a revised version of DSM-III-R criteria for mild cognitive impairment (MCI). This 
revision allowed for identification of cognitive impairment other than memory in 
individuals who did not meet full criteria for dementia. At CSHA-3, clinicians arrived at a 
consensus diagnosis in two stages.  The first diagnostic decision was made without 
reference to the CSHA-2 neuropsychological assessment results. Subsequently, all 
information, including assessment results from CSHA-1 and 2, was reviewed in 
preparation for a final consensus diagnostic decision. It is imperative to note that only 
the incidence diagnoses (i.e., diagnoses that was based on the CSHA-1 criteria) were 
considered in all four of the present investigations. This was done to ensure diagnostic 
consistency, given that the four studies involved all three waves of the CSHA.  
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Appendix B 
ANOVA Summary Tables for Neuropsychological Measures (Study 1) 
Table B1 
Analysis of Variance for 3MS 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 63.96* .53 .000 
G within-group  
 
    Error 
 
 
56 
 
 
(137.77) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
59.14* 
 
43.61* 
.51 
 
.44 
.000 
 
.000 
 
T within- 
 
Group error 
 
 
 
56 
 
 
 
(31.79) 
 
  
Note. Values enclosed in parentheses represent mean square errors.  *p<.001. 
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Table B2 
Analysis of Variance for Retrieval BCRT Variable 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1   63.29** .54 .000 
G within-group  
 
    Error 
 
 
54 
 
 
(59.87) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
  45.25** 
 
12.34* 
.46 
 
.19 
.000 
 
.001 
 
T within- 
 
Group error 
 
 
 
54 
 
 
 
(19.45) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.01 
**p<.001.
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Table B3 
Analysis of Variance for Acquisition BCRT Variable 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 20.88* .28 .000 
G within-group  
 
    Error 
 
 
54 
 
 
(30.26) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
21.87* 
 
18.20* 
.29 
 
.25 
.000 
 
.000 
 
T within- 
 
Group error 
 
 
 
54 
 
 
 
(13.52) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.001. 
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Table B4 
Analysis of Variance for Retention BCRT Variable 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 18.81* .26 .000 
G within-group  
 
    Error 
 
 
55 
 
 
(5.43) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
22.62* 
 
20.34* 
.29 
 
.27 
.000 
 
.000 
 
T within- 
 
Group error 
 
 
 
55 
 
 
 
(2.40) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.001. 
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Table B5 
Analysis of Variance for Letter Fluency Measure (FAS Test) 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 14.58** .22 .000 
G within-group  
 
    Error 
 
 
51 
 
 
(262.22) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
  17.74** 
 
13.71* 
.26 
 
.21 
.000 
 
.001 
 
T within- 
 
Group error 
 
 
 
51 
 
 
 
(29.64) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.01. 
**p<.001. 
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Table B6 
Analysis of Variance for Category Fluency Measure (Animal Naming Test) 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 26.76** .33 .000 
G within-group  
 
    Error 
 
 
55 
 
 
(23.08) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
 11.11* 
 
9.10* 
.17 
 
.14 
.002 
 
.004 
 
T within- 
 
Group error 
 
 
 
55 
 
 
 
(8.48) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.01. 
**p<.001.
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Table B7 
Analysis of Variance for Comparison of Standardized Letter and Category 
Fluency Measures (FAS Test vs Animal Naming Test) 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 23.47* .32 .000 
G within-group  
 
    Error 
 
 
50 
 
 
(2.35) 
  
 
Within subjects 
 
Time (T) 
 
Task (K) 
 
T X G 
 
K X G 
 
T X K  
 
T X K X G 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 21.84* 
 
2.15 
 
14.75* 
 
0.39 
 
0.21 
 
0.01 
.30 
 
.04 
 
.23 
 
.01 
 
.00 
 
.00 
.000 
 
.149 
 
.000 
 
.536 
 
.647 
 
.927 
 
T X K within- 
 
Group error 
 
 
 
50 
 
 
 
(0.28) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.001.  
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Table B8 
Analysis of Variance for Digit Symbol Test 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 13.07* .24 .000 
G within-group  
 
    Error 
 
 
41 
 
 
(161.54) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
 28.29* 
 
1.70 
.41 
 
.04 
.000 
 
.200 
 
T within- 
 
Group error 
 
 
 
41 
 
 
 
(25.16) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.001. 
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Appendix C 
ANOVA Summary Tables for Neuropsychological Measures (Study 2) 
Table C1 
Analysis of Variance for 3MS 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 32.40*** .62 .000 
G within-group  
 
    Error 
 
 
20 
 
 
(100.39) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
6.95* 
 
   10.32** 
.26 
 
.34 
.016 
 
.004 
 
T within- 
 
group error 
 
 
 
20 
 
 
 
(55.29) 
 
  
Note. Values enclosed in parentheses represent mean square errors.  *p<.05. 
**p<.01. ***p<.001. 
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Table C2 
Analysis of Variance for Retrieval BCRT Variable 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1   28.43** .60 .000 
G within-group  
 
    error 
 
 
19 
 
 
(33.45) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
  26.62** 
 
12.24* 
.58 
 
.39 
.000 
 
.002 
 
T within- 
 
group error 
 
 
 
19 
 
 
 
(11.32) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.01 
**p<.001.
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Table C3 
Analysis of Variance for Acquisition BCRT Variable 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 13.36* ..41 .002 
G within-group  
 
    error 
 
 
19 
 
 
(14.36) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
17.07* 
 
18.00** 
.47 
 
.49 
.001 
 
.000 
 
T within- 
 
group error 
 
 
 
19 
 
 
 
(6.91) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.01. 
**p>.001. 
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Table C4 
Analysis of Variance for Retention BCRT Variable 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 13.79* .40 .001 
G within-group  
 
    error 
 
 
21 
 
 
(2.09) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
21.40** 
 
21.40** 
.29 
 
.27 
.000 
 
.000 
 
T within- 
 
group error 
 
 
 
21 
 
 
 
(0.73) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p<.01.  
**p <.001. 
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Table C5 
Analysis of Variance for Letter Fluency Measure (FAS Test) 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 2.74 .14 .116 
G within-group  
 
    error 
 
 
17 
 
 
(59.13) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
 6.05* 
 
0.21 
.26 
 
.21 
.025 
 
.650 
 
T within- 
 
group error 
 
 
 
17 
 
 
 
(30.00) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.05.  
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Table C6 
Analysis of Variance for Category Fluency Measure (Animal Naming Test) 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 18.62** .47 .000 
G within-group  
 
    error 
 
 
21 
 
 
(13.08) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
 14.22* 
 
2.13 
.40 
 
.09 
.001 
 
.159 
 
T within- 
 
group error 
 
 
 
21 
 
 
 
(5.14) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.01. 
**p<.001. 
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Table C7 
Analysis of Variance for Comparison of Standardized Letter and Category 
Fluency Measures (FAS Test vs Animal Naming Test) 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 10.22** .38 .005 
G within-group  
 
    error 
 
 
17 
 
 
(1.02) 
  
 
Within subjects 
 
Time (T) 
 
Task (K) 
 
T X G 
 
K X G 
 
T X K  
 
T X K X G 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 15.17** 
 
1.96 
 
1.79 
 
6.34* 
 
1.23 
 
0.91 
.47 
 
.10 
 
.10 
 
.27 
 
.07 
 
.05 
.001 
 
.180 
 
.199 
 
.022 
 
.284 
 
.354 
 
T X K within- 
 
group error 
 
 
 
17 
 
 
 
(.239) 
 
  
Note. Values enclosed in parentheses represent mean square errors. *p <.05. 
**p<.01.  
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Table C8 
Analysis of Variance for Digit Symbol Test 
 
Source 
 
df 
 
F 
 
Eta2 
 
p 
 
Between subjects 
 
Group (G) 1 7.71* .24 .012 
G within-group  
 
    error 
 
 
18 
 
 
(88.25) 
  
 
Within subjects 
 
Time (T) 
 
T X G 
1 
 
1 
8.82** 
 
1.40 
.33 
 
.07 
.008 
 
.252 
 
T within- 
 
group error 
 
 
 
18 
 
 
 
(13.83) 
 
  
Note. Values enclosed in parentheses represent mean square errors. * p<.05.  
**p <.01 
 
 
